Clinical and experimental links between ... - Wiley Online Library

C L I N I C A L

A N D

E X P E R I M E N T A L

OPTOMETRY cxo_546

4..23

REVIEW

Clinical and experimental links between diabetes and glaucoma

Clin Exp Optom 2011; 94: 1: 4–23 Vickie HY Wong BSc (Hons) Bang V Bui BScOptom MOptom PhD Algis J Vingrys BScOptom PGCertOcTher PhD FARVO FAAO FVCO Department of Optometry and Vision Sciences, The University of Melbourne E-mail: [email protected] Submitted: 11 March 2010 Revised: 11 August 2010 Accepted for publication: 17 August 2010

DOI:10.1111/j.1444-0938.2010.00546.x Glaucoma is a leading cause of blindness. It is a multifactorial condition, the risk factors for which are increasingly well defined from large-scale epidemiological studies. One risk factor that remains controversial is the presence of diabetes. It has been proposed that diabetic eyes are at greater risk of injury from external stressors, such as elevated intraocular pressure. Alternatively, diabetes may cause ganglion cell loss, which becomes additive to a glaucomatous ganglion cell injury. Several clinical trials have considered whether a link exists between diabetes and glaucoma. In this review, we outline these studies and consider the causes for their lack of concordant findings. We also review the biochemical and cellular similarities between the two conditions. Moreover, we review the available literature that attempts to answer the question of whether the presence of diabetes increases the risk of developing glaucoma. At present, laboratory studies provide robust evidence for an association between diabetes and glaucoma.

Key words: diabetes, dyslipidaemia, ganglion cells, glaucoma, hyperglycaemia, intraocular pressure, retina

Diabetes is a leading health priority, as it can cause severe systemic complications, such as retinopathy, neuropathy and nephropathy. This metabolic disorder results from either altered secretion of insulin by the pancreas (type 1 diabetes) or insulin resistance at a cellular level (type 2 diabetes). These changes produce widespread abnormalities in glucose uptake, resulting in hyperglycaemia, as well as abnormal metabolism and formation of lipids (Figure 1), which impact on neurons, blood vessels and glial cells. Indeed, this journal carries an excellent review on glial dysfunction in diabetic eyes.1 Many clinicians will be aware of diabetic retinopathy and its classification, as laid out by the National Health and Clinical and Experimental Optometry 94.1 January 2011

4

Medical Research Council Guidelines for the Management of Diabetic Retinopathy.2 The purpose of this review is not to dwell on the specifics of diabetic retinopathy but to consider whether diabetes predisposes the eye to other disorders, in particular glaucoma. Diabetes has been estimated by the World Health Organization to affect more than 180 million people worldwide. Despite increasing awareness and advances in management of this disease, it is anticipated that the number of sufferers of diabetes will rise to over 360 million by 2030.3 Diabetic eye disease is a leading cause of blindness4–6 in those of working age (aged from 30 to 69 years).7 The Wisconsin Epidemiologic Study of Diabetic

Retinopathy reports that both the duration of the disease and its type (1 or 2) affect the chance of expressing retinopathy.8,9 The prevalence of retinopathy after five years (17 to 29 per cent) increases after 15 years to 78 to 100 per cent. Diabetes is known to increase the risk of other health complications,10 in particular, cardiovascular problems11–13 and cerebral ischaemia.14,15 Of particular interest to eye-care practitioners is the question of whether we should adjust risk estimates for eye disease, such as glaucoma, if a person has diabetes. Epidemiological and laboratory studies provide conflicting evidence of the presence of a relationship between diabetes and glaucoma. This article will review these data to consider whether © 2010 The Authors

Clinical and Experimental Optometry © 2010 Optometrists Association Australia

Links between diabetes and glaucoma Wong, Bui and Vingrys

Pancreas

insulin

insulin resistance glucose uptake

altered fat & lipid metabolism (dyslipidaemia)

cell

(see Fig. 8)

AGEs endothelial cell dysfunction

blood glucose

oxidative stress (pseudohypoxia)

(hyperglycaemia) connective tissue

NO PKC altered vascular supply

Na+/K+-ATPase

MMP-9 neuronal dysfunction

Figure 1. Schematic of the effects that diabetes can have at a cellular level due to hyperglycaemia and dyslipidaemia. AGEs = advanced glycation end products; MMP-9 = matrix metalloproteinases sub-type 9; NO = nitric oxide; PKC = protein kinase C; Na+/K+-ATPase = sodium/potassium ATPase protein.

there is evidence for an increased risk of glaucoma in people with diabetes. GLAUCOMA Glaucoma is the third leading cause of worldwide blindness. Current estimates suggest that more than 60 million people are affected by glaucoma.16,17 Many risk factors have been associated with glaucoma, including family history (first degree relatives), age, race, central corneal thickness, intraocular pressure (IOP), myopia and diabetes.18–21 Of these risk factors, the one that remains controversial is diabetes. MULTIPLE FACTORS LEADING TO RETINAL GANGLION CELL APOPTOSIS AND OPTIC NERVE DAMAGE Intraocular pressure is maintained by a balance between aqueous production and outflow,20,22,23 with an imbalance leading to elevated eye pressure.18,20,24 An elevation in

IOP can manifest at the level of the retinal ganglion cell or lamina cribrosa. Very high levels of IOP will subject retinal cells to ischaemia as well as mechanical stress. This can lead to posterior deformation of the lamina cribrosa, a principal site of injury in glaucomatous neuropathy.25 Mechanical stress18,26,27 at the level of the lamina cribrosa28,29 impairs retrograde transport of neurotrophins,26,27,29–31 such as brainderived neurotrophin factor (BDNF), to retinal ganglion cell soma, thus activating the cell death (or apoptotic) cascade.18,32 Impaired anterograde transport of neurotrophic factors to the lateral geniculate nucleus is also thought to contribute to the onset of apoptosis.20 Long-term vascular and mechanical stresses can produce remodelling of the extracellular matrix, thus altering the compliance of the lamina cribrosa, leading to further injury at the optic nerve.25,33 In addition to mechanical injury, IOP elevation can impair ocular blood flow,34,35 reducing perfusion pressure to retinal neurons. In a normal eye, vascular

© 2010 The Authors Clinical and Experimental Optometry © 2010 Optometrists Association Australia

autoregulation compensates to maintain normal blood flow by changing vascular diameter. Glaucoma pathogenesis may involve abnormal autoregulation,36–39 which produces glial cell activation and retinal ganglion cell loss due to local hypoxia. It is clear that elevated IOP is not the whole story, as from 25 to 60 per cent of glaucoma sufferers appear to have ‘normal’ IOP.40,41 Additionally, many people with ocular hypertension never develop glaucoma. Thus, other risk factors must contribute to the risk of developing glaucoma. Diabetes may be one such risk factor,42 as will be discussed. ASSOCIATIONS BETWEEN DIABETES MELLITUS AND OTHER DISEASES It is clear that those with diabetes are at increased risk of cardiovascular complications and mortality.10,43,44 Whether condition A (for example, diabetes) influences the risk of developing condition B (for example, glaucoma) is defined by the relative risk, which is the ratio of the chance of developing B in groups with or without condition A. Wong and colleagues13 report that patients with diabetic retinopathy and hypertension have a greater relative risk of stroke (2.83) than individuals without diabetes (2.61) and without hypertension (1.97). People with diabetes are two to three times more likely to develop coronary heart disease (CHD).11,12,45 It is of interest that diabetic vascular complications in the eye (including microaneurysms, soft exudates and haemorrhages) mirror those throughout the body, as such ocular changes can be predictive of systemic disease.13,45 HOW MIGHT DIABETES AND GLAUCOMA BE LINKED? Early population studies suggested that those with diabetes are more likely to have elevated IOP and glaucoma.46,47 Previous epidemiological studies have shown that patients with diabetes have a higher IOP (by 2 to 3 mmHg) than those without diabetes.47–51 Ellis and colleagues52 showed that on average their diabetic cohort had more people with ocular hypertension Clinical and Experimental Optometry 94.1 January 2011

5


Author(s)

Location

Armstrong et al46

Study design

Association between diabetes & glaucoma

Odds ratio (95% CL)

incidence

Yes

Bankes54

Bedford, USA

incidence

No

— NA

Kahn et al58

Framingham, USA

prevalence

No

NA

Kahn and Milton59

Framingham, USA (Revision)

prevalence

No

NA

Leibowitz et al264

Framingham, USA

prevalence

No

—

Klein et al50

Beaver Dam, USA

prevalence

Yes

1.68

Tielsch et al48

Baltimore, USA

prevalence

No

1.03

Dielemans et al55

Rotterdam, Holland

prevalence

Yes

3.11

Mitchell et al56

Blue Mountains, Australia

prevalence

Yes

2.12

Ellis et al52

Scotland

incidence

No

1.57

Gordon et al,60 OHTS

USA

prevalence

No

0.40 (0.18–0.92)

Le et al265

Melbourne, Australia

incidence

No

NA

Hennis et al266

Barbados

prevalence

Yes

NA

de Voogd et al19

Rotterdam, Holland

incidence

No

0.65

Pasquale et al267

USA

incidence

Yes

1.82

Miglior et al268

Europe

prevalence

No

0.89 (0.36–2.17)

Chopra et al,269 Latino Eye Study

Los Angeles USA

prevalence

Yes

1.4

Gordon et al,62 OHTS

USA

additional data

No

0.70 (0.45–1.10)

Table 1. Summary of epidemiological trials considering the association between diabetes mellitus and open-angle glaucoma. NA = not applicable; CL = confidence limits.

(IOP greater than 21 mmHg). Oshitari and associates53 suggest that IOP elevation (approximately 2.5 mmHg) has a modest linear correlation with the severity of diabetic disease (HbA1c and IOP: r = 0.15). In contrast, Bankes54 found no IOP differences between the diabetic and nondiabetic groups. Although any IOP increase in diabetic eyes is small, it might contribute to increased stress on the ganglion cells. Several larger scale clinical trials, including the Beaver Dam,50 the Rotterdam55 and the Blue Mountains Eye56 studies, report an increased risk of openangle glaucoma in people with diabetes, however, no evidence for an association was reported57 in the Baltimore Eye Survey,48 the more recent Rotterdam Study19 and the Framingham Eye Study.58,59 Thus, Clinical and Experimental Optometry 94.1 January 2011

6

there is inconsistency among epidemiological studies from the past four decades (Table 1). Why might such discrepancies exist? It is difficult to reconcile these studies, as they have varying diagnostic, assessment criteria and statistical approaches. For example, a recent reanalysis of data from the Rotterdam eye study19 shows that diabetes is not a risk factor for glaucoma. This contradicts the earlier finding from the same population that there was increased risk.55 These conflicting outcomes arise due to a redefinition of primary open angle glaucoma (POAG), which substantially reduced the number of participants. A similar inconsistency has been identified by the authors of the Ocular Hypertension Treatment Study (OHTS). Initial multivariate analysis from the OHTS suggested that diabetes was pro-

tective against conversion from ocular hypertension to glaucoma,60 however, more recent analysis suggests that both the European Glaucoma Prevention study (EGPS) and the OHTS were underpowered to find an effect.61 The OHTS authors acknowledge that patient self-reporting of diabetes and their exclusion criteria may have produced a diabetic cohort that was atypical,62 leading to the observed protective outcome. As many of the above studies do not specifically set out to consider a link between these two conditions, their selection and diagnostic criteria (self-report, glucose tolerance testing) differ substantially. As such, the presence of opposing outcomes may not be surprising. Given this background of conflicting epidemiology, we consider whether there is other © 2010 The Authors



Figure 2. Effect of STZ-induced diabetes on the optic nerve and retina.74 Photomicrographs using methylene blue stained cross-sections of peripheral retina from a control (A) and a STZ animal (B). No significant differences are evident in the gross anatomical structures of these two sections. Methylene blue-stained sections of the optic nerve showed similar optic nerve area in both control (C) and STZ-diabetic (D) groups. In the (D) STZ-diabetic section, nerve fasicle area was significantly reduced and an increased proportion of the optic nerve was taken up by blood vessels (arrowhead) and connective tissue (large arrow). PRL = photoreceptoral layer; ONL = outer nuclear layer; OPL = outer plexiform layer; INL = inner nuclear layer; IPL = inner plexiform layer; GCL = ganglion cell layer; * = represent myelinated axons. Scale bar: (A, B) = 40 mm; (C, D) = 10 mm.

clinical and laboratory-based evidence for a relationship between diabetes and glaucoma. LABORATORY EVIDENCE LINKING DIABETES AND GLAUCOMA

Anatomical changes in diabetes and glaucoma The presence of hyaline bodies particularly in the ganglion cell and retinal nerve fibre layer in post-mortem eyes of patients with diabetes63 suggests that there is inner retinal cell death. Increased cellular apoptosis has been well documented in diabetic

eyes using DNA terminal dUTP nick end labelling (TUNEL),5,64–70 which stains damaged or fragmented DNA. In addition, many studies have shown significant increases in pro-apoptotic factors, such as Bax.71 Ganglion cell axon atrophy has been observed in BB/W-rats, a naturally occurring model of type 1 diabetes.72 Similarly, NeuN (neuron-specific nuclear protein) labelling was found to be significantly reduced in streptozotocin (STZ)-induced diabetic rats, which indicates significant neuronal losses.73 STZ-induction is a common animal model of type 1 diabetes, as this toxin is employed to target and destroy pancreatic b-cells, leading to loss of


insulin production and a resultant increase in blood glucose levels (Figure 1). Barber and coauthors68 showed in STZdiabetic rats that the ganglion cell, inner plexiform and inner nuclear layers are significantly thinned, whereas the outer plexiform and outer nuclear layers are not. Bui and collaborators74 showed that structural changes were present at the optic nerve (Figure 2), including a reduction in myelin sheath thickness (control: 0.25 versus STZ: 0.22 mm), nerve fascicle area (control: 0.22 versus STZ: 0.20 mm2) and increased blood vessel/connective tissue ratio in diabetic rats 12 weeks after STZ-induction. At this time there were no significant differences in the gross structural integrity of STZ-retina (Figure 2). These optic nerve changes might account for the presence of ganglion cell dysfunction in STZ rats, as measured using the electroretinogram (ERG, Figure 3A). Consistent with findings in diabetic animal models, Sugimoto and associates75 employed high resolution optical coherence tomography and found a significant reduction in retinal nerve fibre thickness, even though total retinal thickness was increased in human diabetic eyes without retinopathy. Using a similar approach, van Dijk and co-workers76,77 have found that people with type 1 diabetes (minimal retinopathy) showed a significant reduction in ganglion cell (paracentral retina) and retinal nerve fibre (at the macula) layers, with little change in outer retinal layers. Moreover, ganglion cell layer thickness was found to show a strong correlation with the duration of diabetes.77 Thus there is evidence that diabetic neuropathy has a greater effect on the inner retina, as is the case in glaucoma.78,79

Functional changes in diabetes and glaucoma In addition to the anatomical evidence, the presence of neuropathy can be quantified using functional measures, such as the ERG, of the eye’s response to light. This approach has been employed extensively in studies of diabetes and glaucoma. A temporary decline of rod photoreceptoral function has been observed as soon as two days after the induction of STZClinical and Experimental Optometry 94.1 January 2011

7


500 µV

control

A

diabetic

0

50

100

150

B

200

r = 0.75 p < 0.001

25 µV

pSTR

pSTR (µV)

10

0

-10 nSTR 0

100

200

300

0

400

5

10

15

CTGF fold increase

time (ms)

Figure 3. Effects of STZ-induced diabetes on outer and inner retinal function and its relationship to connective tissue growth factor (CTGF).74 (A) Representative waveform collected using a bright flash (upper traces, 1.58 log cd.s.m-2) to give the a-wave (photoreceptoral response) and the b-wave (ON-bipolar cell response) for the citrate-control group (grey line) and STZ-diabetic group, 11 weeks after STZ induction (bold line). Also included is a waveform collected using a dim stimulus (lower traces, collected using a dim flash -4.96 log cd.s.m-2), which shows that the STR was more affected. (B) Relationship between STR amplitude (positive component, pSTR) and change in connective tissue growth factor (CTGF) expression for citrate-control (unfilled) and STZ treated (filled) animals.

diabetes.80 This returns to normal after two weeks and thereafter shows a more gradual attenuation between four and 12 weeks. It is believed that some of this outer retinal dysfunction is caused by impaired sodium/potassium (Na+/K+)ATPase activity81,82, which produces a smaller dark current and thereby a smaller a-wave. Altered retinal function can arise from diabetic dyslipidaemia (Figure 4) as supplementing omega-3 fats by dietary means prevents some diabetic-induced neuronal dysfunction.83 Diabetic rats fed a diet rich in omega-3 fatty acids (fish oil), had normal polyunsaturated fatty acids (PUFA) profiles and returned functional responses similar to citrate-treated controls animals (control-omega-3 fed; -560 ⫾ 31 versus STZ-omega-3 fed; -567 ⫾ 32 mV) as shown in Figure 5. Those STZ-diabetic rats fed an omega-6 rich diet show an exaggerated functional deficit (STZ-omega-6 Clinical and Experimental Optometry 94.1 January 2011

8

fed; -351 ⫾ 38 versus STZ-omega-3 fed; -567 ⫾ 32 mV). INNER RETINAL RESPONSE

Oscillatory potentials (OPs) are high frequency, small amplitude wavelets that reside on the b-wave (ON-bipolar cell function) of the ERG.84,85 Oscillatory potentials are thought to arise from inner retinal feedback pathways involving amacrine cells. Studies in humans reveal that oscillatory potentials are reduced early in diabetic retinopathy,86–88 well before ERG a-wave (photoreceptoral function) or b-wave changes.87,89 Uccioli and colleagues90 reported that oscillatory potentials were reduced 10 years after the onset of diabetes, without any a-wave or b-wave loss. Other studies have associated oscillatory potential attenuation91–94 with an accumulation of g-amino butyric acid (GABA) in the inner retina.92 Studies

employing pharmacological inhibitors of the GABAergic pathway report modulation of oscillatory potential.95,96 In addition, inhibition of glycinergic pathways modify the oscillatory potentials.97,98 Taken together, these studies suggest that the inner retinal inhibitory pathways are damaged by diabetes. Consistent with this possibility, Gastinger, Singh and Barber99 have found that the dopaminergic and cholinergic amacrine cells (also GABAergic) are lost early in diabetes. In agreement with findings in people with diabetes, STZ-diabetic rats show delayed oscillatory potential implicit time (at 12 weeks control; 28 ⫾ 0.5 versus STZ; 33 ⫾ 0.9 ms)80,91 and reduced (at 12 weeks control; 107 ⫾ 7 versus STZ; 76 ⫾ 7 mV) oscillatory potential amplitude,80,100,101 as shown in Figure 6. Layton, Safa and Osborne102 and Bui and coauthors74 reported a reduction in both oscillatory © 2010 The Authors



Oscillatory potentials

a-wave

Safflower oil

2

Diabetic effect (STZ-Con/Con)

b-wave

1

0

-1 LA 18:2

AA 20:4 DPA 22:5 DPA 22:5 DHA 22:6

Omega 6

Figure 4. The relative effect of diabetes on retinal PUFA incorporation in STZ rats (relative to the control group) shows abnormally high levels of linoleic acid (LA 18:2) and docosapentaenoic acid (DPA 22:5) due to insulin deficiency (only significant data shown from Yee and colleagues83). This backlog of omega-3 (DPA 22:5) translates to reduced longchain fatty acids that impact on eicosanoid inflammatory and neuroprotectin production. LA = linoleic acid; AA = arachidonic acid; DPA = docosapentaenoic acid; DHA = docosahexaenoic acid.

potential and b-wave amplitudes (Figure 3A), which implies that the changes in oscillatory potential may reflect losses of ON-bipolar cell b-wave response. Of note, Yee and associates83 showed that anomalies of the oscillatory potential were correlated with high blood glucose (rs = -0.53, p < 0.05), whereas the b-wave was not (rs = -0.29, not significant) and attenuation of oscillatory potentials could not be reversed by omega-3 fatty acid supplementation despite improvements in the b-wave (Figure 5, lower panel). This observation suggests the possibility of two lesions in the retina, with one being lipid dependent (outer retina)

Fish oil

Omega 3

Figure 5. Fatty acid supplementation and its effect on retinal function in diabetic rats.83 Function was measured using fullfield electroretinogram (ERG). Upper panel shows that all ERG components are reduced (a-wave, b-wave and oscillatory potentials) in STZ-diabetic rats fed with a diet rich in omega-6 fatty acids (safflower oil). On the other hand, STZ-animals given a diet rich in omega-3 (fish oil) had improved a-wave and b-wave responses but still had smaller oscillatory potentials.

and the other being blood glucose related (inner retina).83 GANGLION CELL AND VISUAL PATHWAY

As discussed above, there is evidence for inner retinal damage in diabetes. Whether this manifests in terms of ganglion cell function has been assessed using skin electrodes placed above the occipital lobes to measure visual evoked potentials (VEP).103 Parisi and Uccioli104 showed that people with type 1 diabetes have reduced VEP amplitudes and slower implicit times compared with agematched controls. Similarly, the photopic negative response (PhNR), a cone-driven


ganglion cell response,105–107 has also been shown to be affected by diabetes, with smaller amplitudes associated with greater disease severity. Interestingly, a reduction in the PhNR has also been observed in patients with open-angle glaucoma and in a primate model of experimental glaucoma.105,106,108 The pattern ERG (pERG), recorded to a high contrast reversing checker board stimulus, is an excellent indicator of ganglion cell function.86,106 The pERG is abnormal in optic nerve diseases and glaucoma,106,108 as well as in type 1 diabetic retinopathy.86,104 Although the above studies show that there is ganglion cell dysfunction in diabetes, this might Clinical and Experimental Optometry 94.1 January 2011

9


simply arise due to changes in the outer retina. The integrity of ganglion cells can also be assessed using very dim flashes, which

produce a small ERG waveform near absolute scotopic threshold.109–114 In rodents, this response, termed the scotopic threshold response (STR), is sensitive to IOP

Figure 6. The effect of diabetes on oscillatory potentials (OPs) arising from the inner retina.80 At 12 weeks following STZinduction, diabetic animals showed smaller and slower OP waveforms (unfilled) compared with citrate-control OPs (filled). This is consistent with a deficit in inner retinal function.

A

RmP3

130

Vmax

Amplitude change (STZ/control, %)

Amplitude change (STZ/control, %)

130

100

elevation115,116 and is lost following optic nerve transection.113 In the absence of IOP elevation, Bui and colleagues74 showed that the scotopic threshold response was more affected (Figure 3A) and was affected earlier than responses arising from the outer retina in STZ-diabetic rats (Figure 7).117 More specifically, ganglion cell dysfunction (STR: -85 ⫾ 8 per cent reduction) was greater than photoreceptoral (a-wave: -12 ⫾ 7 per cent) and ON-bipolar cell (b-wave: -18 ⫾ 4 per cent) dysfunction. The level of scotopic threshold response dysfunction showed some association with increased connective tissue growth factor (CTGF, Figure 3B), consistent with the idea that changes in connective tissue may be related to cell injury in diabetes (as will be discussed below). Thus, anatomical and functional evidence exists to suggest that diabetes and glaucoma share many similarities. It appears that in both cases, inner retinal neurons may be more susceptible to these conditions than neurons that reside in more distal layers of the retina.

B

OPS pSTR

100

70

40

70 4

8

Weeks post-STZ

11

4

8

11

Weeks post-STZ

Figure 7. The time course of functional change in STZ-induced diabetes.117 Normalised change (relative to baseline) in amplitude (mean ⫾ SEM) measured at four, eight and 11 weeks for (A) photoreceptoral (a-wave or RmP3, filled), ON-bipolar cell (b-wave or Vmax, unfilled) function and (B) inner retinal function (OP, filled and pSTR, unfilled). Panel (A) shows that at four weeks, the photoreceptoral and ON-bipolar cell response was not affected. At eight weeks, the photoreceptoral response was actually enhanced. At 11 weeks, photoreceptoral and ON-bipolar cell functions were not significantly changed. Kohzaki, Vingrys and Bui117 noted that an average of the ON-bipolar cell Vmax parameter over the three times (four, eight and 11 weeks) showed a significant decrease in ON-bipolar cell response (-6 ⫾ 3%; p = 0.004). Panel (B) shows that at each time, inner retinal responses (OPs and STR) were more affected. In particular, the OPs were reduced from eight weeks onwards, whereas the pSTR was significantly affected as early as four weeks. Clinical and Experimental Optometry 94.1 January 2011

10



Studies of IOP elevation in diabetes Vesti and Trick118 have reported that diabetes exacerbates visual dysfunction in ocular hypertensive patients. The authors showed that pERG waveforms, colour vision and contrast sensitivity were more attenuated in ocular hypertensive patients with diabetes than in people with ocular hypertension without diabetes. Quigley and coauthors119 reported an association between diabetes and nerve fibre atrophy, although they failed to show any significant difference in the severity of visual field loss between glaucoma sufferers with or without diabetes. Several studies have attempted to address directly the issue of whether diabetes influences the risk of glaucoma, by considering the effects of IOP challenge in normal and diabetic animals. Casson and colleagues120 reported that an acute hyperglycaemic state induced either by STZdiabetes or glucose injections in rats protected the ON-bipolar cell b-wave component of the ERG from acute, severe IOP challenge. Several days following IOP elevation to 100 mmHg, larger b-waves were measured in STZ-induced diabetic eyes than in the non-diabetic control group. More recently, Holman and colleagues121 showed that short-term hyperglycaemia (10 days post STZ-diabetes) protected retinal ganglion cells from hypoperfusion induced by ligation of the common carotid arteries. Both these studies suggest that in the short-term, an increase in glucose levels is protective for bipolar cells against ischaemic insult, most likely due to the metabolic advantage provided by this substrate during ischaemic stress. This may not be the case for retinal ganglion cells, particularly during a much milder and chronic IOP challenge, as is the case in glaucoma. Kanamori and co-workers69 showed that chronic ocular hypertension (four weeks, from 13 to 29 mmHg), induced by cauterising three episcleral veins, was more detrimental in STZ-diabetic rat retina compared with control eyes. The authors showed that there was an increased apoptosis in the inner retina in high IOP challenged STZ-treated rats. More specifically, larger cell bodies undergoing apoptosis

were at the level of the ganglion cell layer. Additionally, there were smaller cell bodies that stained for TUNEL in the inner nuclear layer, which may be Müller or amacrine cells. This outcome is consistent with the idea that diabetes exacerbates inner retinal neuronal injury in a model of chronic glaucoma. It is worth noting that IOP increased apoptosis by the same amount in STZ-diabetic and control eyes. This suggests that existing retinal ganglion cell dysfunction (Figures 3A and 7) or loss in diabetes is ‘additive’ to the ganglion cell dysfunction/death produced by IOP stress. If these data translate to humans, it may be that the presence of diabetes may produce an earlier manifestation of detectable visual field loss in glaucoma. There may also be a more aggressive disease development in diabetic eyes, as evidenced by the finding that people with diabetes are more likely to have bilateral disease in normal tension glaucoma.122 Given the above evidence, the next section considers potential mechanisms that link diabetes and glaucoma. DISEASE MECHANISMS COMMON TO DIABETES AND GLAUCOMA Diabetes produces abnormalities in glucose as well as lipid metabolism (Figure 1). The effects of hyperglycaemia have been studied extensively, however, less attention has been paid to lipid anomalies and the potential role that this has in promoting neuronal dysfunction and a modified inflammatory status. These factors should not be thought of in isolation, as hyperglycaemia will cause glycation of lipids123 aggravating the diabetesinduced changes.

Dyslipidaemia Studies in humans and animals have shown that lipid composition and metabolism are abnormal in diabetes.83,124–127 Diabetic rats show increased liver cholesterol production.128 Cell membranes of rat retinal neurons (Figure 4) and erythrocytes in people with type 1 diabetes, show a marked decrease in polyunsaturated fatty acids at the expense of docosahexaenoic acid (DHA).83,126 Docosahexaenoic acid is an important fatty acid that promotes neural


function,129,130 and polyunsaturated fatty acids derivatives (eicosanoids) give rise to inflammatory modulators and neuro-protecting substrates (neuroprotectins).131,132 Thus dyslipidaemia may be a key link between diabetes and cardiovascular complications, and potentially neuropathy (Figure 8). It is thought that reduced insulin production or increased insulin resistance leads to elevated secretion of triglycerides from the liver as well as impaired clearance of lipid (Figure 8). This imbalance in fats leads to a reduction in plasma levels of high density lipoproteins (HDL) and an increase in low density lipoproteins (LDL).133 There is an associated increase in cellular fatty acid uptake and abnormal fatty acid metabolism134 (Figure 1). Membrane lipids are metabolised in the cyclo-oxygenase and lipoxygenase pathways to produce short-lived local hormones, such as leukotrienes, prostaglandins, prostacyclins and thromboxanes.135,136 The omega-3 eicosanoid derivatives are anti-inflammatory, antiapoptotic and enhance fluid129 or blood flow compared with the omega-6 family. Diabetes produces an imbalance that favours omega-6 derivatives by about 2.5 times83 and will promote a proinflammatory environment. It is increasingly apparent that pro-inflammatory factors are present in glaucoma137 and many other eye diseases.138,139 Abnormalities in neuronal fatty acid uptake can modify cellular energy production as fatty acid and glucose metabolism are linked.134 The abnormal lipid processing in diabetes will increase cellular fatty acid uptake, which reduces glucose uptake (Figure 1), as evidenced by reduced glucose transporter expression in the retina140 and retinal pigment epithelial cells in vitro.141 Less cellular glucose impairs energy production, which can deplete the antioxidant capacity of neuronal tissues. Increased oxidative stress is known to be important in both diabetes and glaucoma pathogenesis.142 Finally, Bazan132 has shown that long-chain derivatives of the omega-3 family of fatty acids, called neuroprotectins, are potent antiapoptotic molecules that down regulate Clinical and Experimental Optometry 94.1 January 2011

11


Bax activity. Thus, lipid changes associated with diabetes (Figure 4 in STZ-diabetic rats) could promote apoptotic pathways.

diabetes insulin insulin resistance

hyperglycaemia

Vascular dysregulation

(see Figure 1)

liver secretion of triglycerides

clearance of lipid and lipoproteins

compromised cardiovascular function

diabetic dyslipidaemia HDL

smaller denser LDL

fatty acid uptake fatty acid metabolism omega-3

cells (see Figure 1)

eicosonoids prostaglandins

cell membranes

mitochondrial metabolism

AGEs

inflammation

endothelial cell dysfunction

PKC

membrane bound protein function (e.g. Na+/K+-ATPase)

altered perfusion pressure

oxidative stress

neuronal dysfunction

Figure 8. Schematic diagram of the effects of diabetes on lipid metabolism and those pathways that can impact on cellular process, potentially leading to neuronal dysfunction. HDL = high density lipoproteins; LDL = low density lipoproteins.

Empirical changes

Clinical changes Preproliferative

Proliferative

Basement membrane thickening

Microaneurysms Intra-retinal microvascular abnormalities

Neovascularisation

Pericyte loss

Microvascular occlusions Venous beading and dilation

Vitreous or pre-retinal haemorrhage

Increased permeability of inner and outer blood-retinal barriers

Retinal haemorrhages and microaneurysms

Neuronal apoptosis

Hard exudates and retinal oedema Capillary non-perfusion

Table 2. Stages of diabetic retinopathy, adapted from Phipps, Fletcher and Vingrys80 and Watkins7 Clinical and Experimental Optometry 94.1 January 2011

12

Much of the research into diabetic eye disease has focused on vascular complications (Table 2), which manifest clinically as intraretinal haemorrhages, localised ischaemia (cotton wool patches), basement membrane thickening (vascular tortuosity) and loss of pericytes (microaneurysms).6,7,143–147 Proliferative diabetic retinopathy occurs when growth factors, such as vascular endothelial growth factor (VEGF, a potent angiogenic and vascular permeability factor148–150) promote neovascularisation,147,151,152 which can produce neovascular glaucoma.153 Those with type 2 diabetes are more likely to develop non-proliferative retinopathy,6 including sight-threatening macular and retinal oedema.7 These patent clinical signs are often preceded by reduced retinal blood flow,154–156 which can render tissues hypoxic and trigger the release of VEGF.157 Blood flow abnormalities have been attributed to changes in endothelial cells and intracellular microfilaments of the vascular endothelium as has been found in STZ-diabetic rats.158 Cringle and colleagues159 reported that after five weeks of STZ-diabetes, rats showed increased retinal blood flow compared with controls. This was supported by Yu and co-workers,158 who reported abnormalities in F-actin stress fibre arrangement in superficial diabetic retinal capillaries as early as five weeks following STZ induction. This change in F-actin stress fibre is consistent with the increased blood flow (Table 3). Regardless of the absolute level of blood flow, growing evidence suggests that diabetic eyes have a reduced capacity to autoregulate blood flow, when challenged by reduced ocular perfusion pressure (the balance between blood pressure and IOP). Studies have found that people with diabetes show impaired vasodilation in response to flickering light.160,161 This suggests the presence of endothelial cell dysfunction and may involve abnormalities in nitric oxide (NO), a potent vasodilator.162 © 2010 The Authors



VASCULAR DYSFUNCTION STZ/diabetes

Ocular hypertension/ glaucoma

↑ vascular permeability81,152 ↑ PKC levels (thickening of basement membrane, affect VEGF release, Na+/K+-ATPase activity)81

↑ PKC levels (direct effect to altering trabecular meshwork properties)188

↑ VEGF release148,149,164,187

↑ VEGF release–rubeotic (neovascular) glaucoma153

altered blood flow, autoregulation154–157,159–161,201,270

↓ blood flow, altered autoregulation35–37,39,163,271

altered vasoactivity272 absence of F-actin cytoskeleton (5 weeks diabetic retina)158

Table 3. Summary of vascular dysregulation reported in clinical/experimental diabetes and in ocular hypertensive/ glaucomatous studies

It is of interest that abnormal autoregulation is implicated in the pathogenesis of glaucoma,36,39,163 providing a potential link between the two conditions. HYPOXIA

Reduced blood flow produces tissue hypoxia, which leads to increased VEGF production that promotes neovascularisation. In diabetic retinopathy, over expression164 and increased stability of VEGF mRNA165 have been associated with hypoxia-inducible factor-1 (HIF-1a),166–168 which accumulates when oxygen levels fall below 10 per cent. Importantly, HIF-1a is increased in ganglion cells after elevated IOP168 and in the retina and optic nerve head of human glaucomatous eyes.169 Arden and associates170 suggested that the retina is particularly prone to neovascularisation because of its high metabolic demand. The authors observed that neovascularisation does not occur in diabetic brains, which is less metabolically demanding than the retina. Similarly neovascularisation was absent in those with diabetes who also had rod photoreceptor degeneration (retinitis pigmentosa) or pan-retinal photocoagulation.171 Consistent with this idea, diabetic mice with loss of rod photoreceptors showed reduced levels of VEGF.172

Oxidative stress There is a fine balance between the levels of reactive oxygen species (for example, O2-, H2O2, OH) and the eye’s ability to protect against them (anti-oxidants). This imbalance is known as oxidative stress173 and in diabetic eyes,162 it can be caused by hypoxia,174 hyperglycaemia-induced formation of advanced glycation endproducts (AGEs),175 glycosphingolipid metabolic dysfunction,176 over activation of aldose reductase177 and mitogenactivated protein (MAP) kinases,178 as well as mitochondrial abnormalities.71,142 In addition, abnormal lipid metabolism will impair mitochondrial function, leading to compromised antioxidant systems.134 It is pertinent that increased oxidative stress, as evidenced by nitric oxide overproduction, has been reported in both glaucoma and diabetes (Table 4).162,179 POLYOL-SORBITOL PATHWAY ABNORMALITIES IN DIABETES

Under normal circumstances (that is, normoglycaemia), glucose is metabolised to glucose-6-phosphate by hexokinase. Nonphosphorylated glucose is converted to sorbitol, a reaction catalysed by aldose reductase in the polyol-(sorbitol) pathway (Figure 9). Sorbitol is then converted to fructose via sorbitol dehydrogenase. In a


hyperglycaemic environment, the polyolsorbitol pathway becomes overwhelmed by high levels of sorbitol,177,180,181 resulting in a metabolic imbalance.182 One manifestation is an increased ratio of nicotinamide adenine dinucleotide (NADH)/ nicotinamide adenine dinucleotide phosphate (NAD+).182,183 This change in redox state impacts many metabolic pathways, which can increase nitric oxide formation,183 leading to endothelial cell182 and glial cell dysfunction.67 Consistent with this idea, diabetic mice with normal aldose reductase showed oxidative stress (elevated superoxide formation) and neuronal apoptosis (increased c-Jun NH2-terminal kinase activity, DNA damage).184 On the other hand, mice lacking aldose reductase showed little oxidative stress and neuropathy when rendered diabetic. Studies by Winkler and co-workers185 and Diederen and collaborators186 challenge the ‘pseudohypoxia’ hypotheses, as these authors failed to find a significant difference in NAD+ to NADH ratio in STZ-diabetic retina. Nevertheless the above studies are in agreement that in the diabetic eye, there is increased anaerobic metabolism, as evidenced by a six- to seven-fold increase in lactate production.174,185,186 Impaired energy production would make neurons less able to cope with stress. PROTEIN KINASE C PATHWAY

Increased vascular permeability and changes in retinal blood flow observed early in diabetes have been associated with the activation of diacylglycerol and protein kinase C (PKC).81 PKC is an intracellular signalling protein and has a regulatory role in modulating neural and vascular activities. Excess PKC leads to thickening of vascular basement membranes in diabetic eyes.151 This impairs oxygen exchange producing relative hypoxia and oxidative stress and ultimately VEGF release.187 Increased PKC can also produce vasodilation,81 which may contribute to abnormalities in blood flow reported in some diabetic retinas.154,155,159 Changes in PKC are also known to affect extracellular matrix regulation,188 which is pertinent in two ways. First, PKC activation Clinical and Experimental Optometry 94.1 January 2011

13


OXIDATIVE STRESS STZ/diabetes

Ocular hypertension/ glaucoma

↑ NO production162,183

↑ NO production162,179

iNOS (eg: high immunoreactivity in human Müller cells)202–206

↑ NOS (3 isoforms) at ONH; ↑ NOS-2 in astrocytes and microglia179,213

↓ nNOS & eNOS162,205

↑ nNOS presence and iNOS activity in astrocytes at the optic nerve head162,179

AGEs formation175 aldose reductase formation (↑ sorbitol production)177,181 ↑ NADH/NAD+ ratio182,183

↓ NADPH-diaphorase reactivity in ciliary muscle, trabecular meshwork and Schlemm’s canal (link to NOS)273

↓ Na+/K+-ATPase activity (possibly due to PKC elevation, dyslipidaemia)80–82,192,193,198

the lipid composition of cell membranes192,193 or elevated PKC and sorbitol,81,82 all of which occur in diabetes. A reduction in Na+/K+-ATPase activity can impair ionic homeostasis and the activity of retinal194–196 and peripheral nerves,80,197 as well as the retinal pigment epithelium.198 PKC can modulate Na+/K+ATPase activity,199 thereby affecting the dark current and thus, the ability of photoreceptors to transduce light to a chemical signal. Alternatively, a metabolic switch in diabetic retina from aerobic to the less efficient anaerobic pathway would substantially reduce the activity of Na/K+ATPases. Ames and colleagues200 estimate that almost half the energy produced via aerobic pathways is needed to sustain sodium transport. A reduction in energy availability would be highly detrimental.

MAP kinase formation178 NITRIC OXIDE

glycosphingolipid metabolic dysfunction176 mitochondrial abnormalities tissue hypoxia

70

150,157,174

mitochondrial abnormalities

142

tissue hypoxia157

accumulation of HIF-1a associated with VEGF mRNA over expression164 NOS = nitric oxide synthase; iNOS = inducible NOS; eNOS = endothelial NOS; nNOS = neuronal NOS

Table 4. Summary of evidence for oxidative stress reported in studies of clinical/experimental diabetes and in ocular hypertensive/glaucomatous conditions

leads to elevation of several matrix metalloproteases (MMP-1, -3, -9) and tissue inhibitors of metalloproteases (TIMP)-1 but decreased TIMP-2 in the trabecular meshwork.188 A change in the trabecular meshwork can increase impedance to aqueous outflow producing IOP elevation. Khurana and colleagues189 showed that a PKC inhibitor (GF109203X) produced a 46 per cent increase in aqueous outflow in perfused porcine eyes. Second, over expression of MMP-9 has been associated with activation of astrocytes as well as structural changes at the optic nerve head in patients with diabetes.190,191 Structural Clinical and Experimental Optometry 94.1 January 2011

14

changes at the optic nerve head are seen in STZ-diabetic rats (Figure 2). PKC-induced changes to connective tissues could influence lamina cribrosa compliance, making the optic nerve more susceptible to the mechanical effects of IOP elevation. ALTERATIONS TO NA+/K+-ATPASE ACTIVITY

Sodium/potassium (Na+/K+)-ATPase is a ubiquitous plasma membrane protein. It acts to maintain transmembrane potential by pumping potassium in and sodium out of cells in an energy dependent manner. Na+/K+-ATPase activity can be altered by

Nitric oxide is a vasoactive substrate and an intracellular messenger. Excessive production of nitric oxide, via nitric oxide synthase (NOS), can induce oxidative stress promoting apoptotic cell death and impaired vascular autoregulation.162,201,202 There are several subtypes of NOS: neuronal NOS (nNOS), endothelial NOS (eNOS) and inducible NOS (iNOS). Hyperglycaemia increases iNOS activity, leading to excess nitric oxide, which is thought to contribute to diabetic retinopathy.202–206 As early as one to three weeks after STZ-induction, fewer eNOSand nNOS-positive cells were found in diabetic rat retina compared with control retina.201,207 Abu El-Asrar et al205 found elevated iNOS immunoreactivity in Müller cells in human diabetic retina. Müller cells span almost the entire width of the retina and are important for neuronal support.1,208 Kawasaki, Otori and Barnstable209 suggest that Müller cell dysfunction may be an early contributor to neuronal injury due to their critical role in extracellular glutamate uptake and recycling.210 Excessive nitric oxide has been suggested to increase vascular resistance and reduce blood flow at the retina and optic nerve head211 in patients with primary open-angle glaucoma. Like diabetes, increased nNOS and iNOS activity has © 2010 The Authors



NADP+

NADPH

hexokinase

glucose-6-phosphate

glucose

aldose reductase

TCA cycle

NADPH NAD+

(normal or enhanced function)

NADP+

sorbitol (excessive)

NADH

metabolic sorbitol imbalance dehydrogenase

oxidative stress

( fructose)

‘pseudohypoxia’

1. abnormal NO formation 2. endothelial/glial cell dysfunction

Figure 9. Schematic diagram of the polyl-(sorbitol) pathway. The top of the schematic reflects glycolysis, the major pathway for glucose utilisation. In normoglycaemia, glucose is metabolised by hexokinase to glucose-6-phosphate. Any non-phosphorylated glucose is converted to sorbitol by aldose reductase, as such, hyperglycaemic conditions (bold) will cause an imbalance in this metabolic pathway, producing ‘pseudohypoxia’ and increase in oxidative stress.

AXONAL TRANSPORT STZ/diabetes Impaired retrograde transport (at optic nerve axons)65

Ocular hypertension/ glaucoma Impaired ortho/retrograde transport (eg: elevated IOP conditions, proportional increase)18,28,32,224,225 Axonal cytoskeletal and transport retardation changes226

Deprivation of neurotrophic support65,178,216

Deprivation of neurotrophic support30,32,274–276

↑ MMP-9190

↑ MMP-9190,191,277

Altered growth factor/cytokine activity74,173,227–229

Altered growth factor/cytokine activity188,234

GLIAL CELL CHANGES STZ/diabetes ↑ GFAP activation early in diabetes (ie: Müller cell dysfunction)1,67,68,71,208,239,257

Ocular hypertension/ glaucoma ↑ GFAP activation (ie: Müller cell & astrocyte dysfunction at the optic nerve head)209,241–243,247–249

Table 5. Summary axonal transport abnormalities and glial changes reported in studies of clinical/experimental diabetes and in ocular hypertensive/glaucomatous conditions

been found in people with glaucoma, particularly in astrocytes at the lamina cribrosa.179 A diabetic eye already under stress due to nitric oxide overproduction might

be at risk from additional oxidative injury in glaucoma. Translating these neuroprotection strategies from the laboratory to the clinic has been unsuccessful.212


Several studies have targeted the NOS pathways for pharmaceutical intervention in glaucoma.213–215 Treatments including a NOS substrate (that is, L-arginine) and a nitric oxide donor (nitroprusside and minoxidil) have been administered in an attempt to increase ocular blood flow with some success.215 Additionally, Neufeld213 has reported that the iNOS inhibitor, aminoguanidine, provides neuroprotection in animal models of glaucoma.

Axonal transport abnormalities and neurotrophic factors Impaired retrograde axonal transport can trigger apoptotic cell death,18,32 as neurotrophic factors fail to reach their retinal targets. Similarities between diabetes and glaucoma are summarised in Table 5. In diabetes, clinical and experimental observations have demonstrated neurotrophic deprivation,173,216 likely via impaired retrograde axonal transport.65,217 For example, nerve growth factor, insulin-like growth factor and neurotrophin-3 are reduced in diabetic animals and humans.216,218–221 Reduced brain-derived neurotrophic factor (BDNF) is thought to promote diabetic neuropathy.222,223 Decreased BDNF immunoreactivity has been found in the ganglion cell and inner plexiform layers of STZ-induced diabetic rat retina.222 This may account for degeneration of ganglion cells, dopaminergic amacrine cells and Müller cells in these eyes.222 In agreement with this idea, intravitreal administration of BDNF provided some neuroprotection, particularly for amacrine cells.64,222 Blockage of axonal transport is thought to be a critical factor in glaucoma.32 Several studies have demonstrated deficient axonal transport of radioactivelylabelled amino acid 3H-leucine and horseradish peroxide in non-human primate eyes, at the lamina cribrosa, following IOP elevation.28,224,225 The degree of optic nerve head retro- and anterograde transport impairment is proportional to the level of IOP elevation.225 Pease and colleagues29 showed retrograde transport of BDNF was reduced and its receptor (TrkB) was increased at the optic nerve head in non-human primate experimental glaucoma. This has also been Clinical and Experimental Optometry 94.1 January 2011

15


found in rodent30 and porcine226 models of glaucoma. In diabetic retina, retinal ganglion cells, microglia and pericytes show increased immunoreactivity for connective tissue growth factor,74,227–229 which mediates the activity of transforming growth factor-b (TGF-b), the action of which on connective tissue is important in contractile scarring for wound healing.230 Analogous to VEGF, connective tissue growth factor participates in angiogenesis, vascular proliferation, endothelial cell formation and migration.231 This cytokine is upregulated by increased reactive oxygen species, advanced glycation end-products, as well as tissue hypoxia and hyperglycaemia, which are all present in diabetes.227 Over expression of connective tissue growth factor causes caspase-3 dependent apoptosis.232 Bui and colleagues74 reported elevated connective tissue growth factor in STZtreated rat eyes, which was correlated with ganglion cell dysfunction (Figure 3B). This elevation of connective tissue growth factor was associated with an increase in connective tissue at the optic nerve head (Figure 2D). In glaucoma, elevated connective tissue growth factor and TGF-b expression are thought to alter the activity of MMP and TIMP, which produce abnormal tissue remodelling and turnover.233,234 This can impact at two sites. First, abnormal trabecular meshwork connective tissue can impair aqueous outflow and increase IOP. Second, remodelling of lamina cribrosa extracellular matrix can make the tissue less compliant and susceptible to mechanical stress with elevated IOP, as has been suggested by a number of studies.25,235–238

Altered glial cell support: Müller cells and astrocytes Apart from vascular complications, there is mounting evidence that both neurons and glial cells (including Müller cells, actrocytes and microglia) are affected early in the course of diabetes,68,71,239 prior to vascular changes as reviewed by Fletcher, Phipps and Wilkinson-Berka.1 Glial cells are important for retinal1,240 and optic nerve homeostasis.241–243 They interact with other cells to maintain vascular structure and ionic balance, glutamate Clinical and Experimental Optometry 94.1 January 2011

16

shuttling, metabolic support, mechanical support and the removal of invading organisms and foreign debris.73,241–243 Glial cell dysfunction can be indicated by an increased expression of glial fibrillary acidic protein (GFAP), an intermediate glial protein, which is increased early in diabetes.73,239 Increased glial fibrillary acidic protein immunoreactivity in Müller cells and astrocytes was found to be associated with higher concentrations of sorbitol and fructose in STZ-diabetic rats.67 Thus, diabetes induced changes in the polyol pathway may partly explain glial cell activation.67,233 Other glial cells may also play an important role in diabetic retinopathy. Zeng, Ng and Ling73 observed hypertrophy, as well as an increase in OX42-immunoreactive microglial cells (in the nerve fibre and ganglion cell layers) after four-months of STZ-diabetes. This suggests the presence of chronic inflammation, as these cells are involved in phagocytosis of degenerated neurons in diabetic eyes. It is of interest that an aberrant inflammatory response can increase the vulnerability of the retina to stress.244–246 This is an emerging idea in glaucoma pathophysiology.137 Glial fibrillary acidic protein immunostaining can also be detected in astrocytes at the optic nerve head,247,248 particularly in glaucomatous eyes.249 Recently, Balaratnasingam and associates250 showed that glial fibrillary acidic protein immunoreactivity decreased at six, nine and 12 hours following IOP elevation to 40 to 45 mmHg. In addition, morphological changes could be detected in astrocytes as early as three hours following this IOP insult. In another study,251 high IOP for 12 hours resulted in impaired axonal transport in the lamina and proximal postlaminar regions of the optic nerve head. These outcomes suggest that astrocytes play a role in protecting against axonal injury. Abnormal glial cells appear to be present in diabetes and glaucoma. Glial cell dysfunction, arising from hyperglycaemia and lipid changes in diabetes, might place ganglion cell axons at increased risk of injury from IOP stress.252 Glial cells rapidly take up and deactivate extracellular neurotransmitters, to pre-

vent excessive activation of excitatory receptors. Intracellular calcium build-up via influx and the release of intracellular calcium stores can activate the apoptotic cascade.253,254 Studies in both STZ-rats and people with diabetes reveal that hyperglycaemia is associated with significantly elevated retinal glutamate levels.151,239,255,256 Li and Puro257 showed dysfunction of the glutamate-aspartate transporter in isolated Müller cells from STZ-diabetic rats. Excitotoxic injury can cause cell death, which would compound any IOP related stress.

Altered biomechanical properties of the sclera, lamina cribrosa and optic nerve Elevated IOP can increase stress (force) and strain (localised deformation) at the optic nerve head.25,235,237 A gradual compromise in the collagen fibrils that make up the load-bearing connective tissues237 at the lamina cribrosa and the peripapillary sclera can exacerbate stress and strain on ganglion cell axons and capillary networks that transit this region.25,79,235–238,258,259 Optic nerve head connective tissue changes have been observed following experimental glaucoma in monkey258 and rat.260 These changes can occur with modest IOP elevation of 10 to 20 mmHg above normal levels in rats.260 This connective tissue remodelling alters the biomechanical characteristics of the optic nerve head, increasing the likelihood of posterior deformation of the lamina cribrosa with IOP. Axonal deviation can occur secondary to posterior bowing of the lamina cribrosa261 and posterior optic disc displacement,79,262 which can compromise axonal transport. Diabetes can exacerbate connective tissue remodelling and amplify these biomechanical changes. Chronic hyperglycaemia has been shown to produce glycation of rat tail collagen (type 1) proteins, resulting in the formation of advanced glycation endproducts.263 Application of glucose-6phosphate into collagen gel cell cultures lead to modification of its biomechanical properties, including increased collagen cross-linking and enzymatic degradation.263 Whether diabetes-induced glycation in optic nerve and trabecular © 2010 The Authors



chronic hyperglycaemia/dyslipidaemia biochemical pathways

2 blood vessels

3

4 glia

5

neurons

connective tissues

1 oxidative stress

compliance blood flow axonal transport

endothelial cell dysfunction

autoregulation

ionic support

growth factors

IOP at trabecular meshwork mechanical stress at lamina cribrosa

glutamate uptake

excitotoxicity chronic inflammation

vulnerability to stress hypoxia

e.g. elevated IOP

risk of neurodegenerative disease e.g. glaucoma

Figure 10. Summary of the possible changes resulting from chronic hyperglycaemia and dyslipidaemia seen in diabetes mellitus. These pathways are not meant to imply causation but rather to illustrate the possible ways in which diabetes might promote neurodegenerative diseases such as glaucoma. Much research is needed to define these links.

meshwork connective tissues renders diabetic eyes less able to accommodate IOP fluctuations, requires further investigation. CONCLUSIONS Diabetes mellitus and glaucoma are leading causes of blindness. The epidemiological evidence for an association between the two conditions remains inconclusive. There is a growing body of evidence that the presence of longstanding hyperglycaemia, along with lipid anomalies, may increase the risk of neuronal injury from stress. In particular, the laboratory data provide robust evidence for an association. We illustrate various

pathways whereby diabetes and glaucoma might converge to produce an increased risk of neurodegeneration. These pathways are schematised in Figure 10 and can be summarised as follows. • Altered biochemical pathways compromise cells and also increase oxidative stress. • Vascular changes can reduce blood flow and impair oxygen diffusion. Endothelial cell injury and dysfunction can reduce the capacity for autoregulation to protect against fluctuations in eye and blood pressure. These lead to relative hypoxia. • Glial cell activation can lead to impaired ionic support and possibly reduced glutamate uptake. This might


increase the chance of excitotoxicity. Excessive glial cell activation may also contribute to chronic inflammation. • Changes to neurons may impair their ability to function, including axonal transport, leaving these neurons, which are already vulnerable, under additional stress. • Connective tissue remodelling might reduce compliance at the trabecular meshwork and lamina cribrosa, promoting increased IOP and greater optic nerve head mechanical stress, respectively. Further studies are needed to directly determine mechanisms underlying any potential association between diabetes and glaucoma. Nevertheless, the above literature indicates that clinicians should consider adjusting the risk for glaucoma in patients who have chronic diabetes. Our early work with dietary modification (increased fish oil intake) indicates that some benefits can be expected in people with both diabetes and glaucoma. GRANTS AND FINANCIAL SUPPORT

The authors are supported by NHMRC project grants 400127, 475603, 566570 and 350224. REFERENCES 1. Fletcher EL, Phipps JA, Wilkinson-Berka JL. Dysfunction of retinal neurons and glia during diabetes. Clin Exp Optom 2005; 88: 132–145. 2. Mitchell P, Suriya F, Wong TY, Chua B, Patel I, Ojaimi E. Clinical Practice Guidelines for the Management of Diabetic Retinopathy. National Health and Medical Research Council 2010. [cited 19 November 2009] Available from: http://www.nhmrc.gov.au/_files_nhmrc/file/ publications/synopses/di15.pdf. 3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047–1053. 4. Taylor HR, Pezzullo ML, Keeffe JE. The economic impact and cost of visual impairment in Australia. Br J Ophthalmol 2006; 90: 272–275. 5. Barber AJ. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 283– 290. 6. Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AE, Al-Shabrawey M, Platt DH, Caldwell RW. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003; 19: 442–455. 7. Watkins PJ. Retinopathy. BMJ 2003; 326: 924– 926.

Clinical and Experimental Optometry 94.1 January 2011

17


8. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102: 527– 532. 9. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984; 102: 520– 526. 10. Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 2006; 55: 1463–1469. 11. Ruppert K, Roberts MS, Orchard TJ, Zgibor JC. Cardiovascular disease risk prediction in type 1 diabetes: accounting for the differences. Diabetes Res Clin Pract 2007; 78: 234–237. 12. Cheung N, Wang JJ, Klein R, Couper DJ, Sharrett AR, Wong TY. Diabetic retinopathy and the risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Diabetes Care 2007; 30: 1742–1746. 13. Wong TY, Klein R, Couper DJ, Cooper LS, Shahar E, Hubbard LD, Wofford MR et al. Retinal microvascular abnormalities and incident stroke: the Atherosclerosis Risk in Communities Study. Lancet 2001; 358: 1134–1140. 14. Ding C, He Q, Li PA. Activation of cell death pathway after a brief period of global ischemia in diabetic and non-diabetic animals. Exp Neurol 2004; 188: 421–429. 15. Li ZG, Britton M, Sima AA, Dunbar JC. Diabetes enhances apoptosis induced by cerebral ischemia. Life Sci 2004; 76: 249–262. 16. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol 1996; 80: 389–393. 17. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90: 262–267. 18. Quigley HA. Neuronal death in glaucoma. Prog Retin Eye Res 1999; 18: 39–57. 19. de Voogd S, Ikram MK, Wolfs RC, Jansonius NM, Witteman JC, Hofman A, de Jong PT. Is diabetes mellitus a risk factor for open-angle glaucoma? The Rotterdam Study. Ophthalmology 2006; 113: 1827–1831. 20. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004; 363: 1711–1720. 21. Coleman AL. Glaucoma. Lancet 1999; 354: 1803– 1810. 22. Macknight AD, McLaughlin CW, Peart D, Purves RD, Carre DA, Civan MM. Formation of the aqueous humor. Clin Exp Pharmacol Physiol 2000; 27: 100–106. 23. Civan MM, Macknight AD. The ins and outs of aqueous humour secretion. Exp Eye Res 2004; 78: 625–631. 24. Sommer A. Intraocular pressure and glaucoma. Am J Ophthalmol 1989; 107: 186–188. 25. Burgoyne CF, Downs JC, Bellezza AJ, Suh JK, Hart RT. The optic nerve head as a biomechanical structure: a new paradigm for understanding the role of IOP-related stress and strain in the pathophysiology of glaucomatous optic nerve head damage. Prog Retin Eye Res 2005; 24: 39–73. 26. Quigley HA, Flower RW, Addicks EM, McLeod DS. The mechanism of optic nerve damage


18

27.

28.

29.

30.

31.

32.

33.

34.

35.

36.

37.

38.

39.

40.

41.

42.

in experimental acute intraocular pressure elevation. Invest Ophthalmol Vis Sci 1980; 19: 505– 517. Quigley HA, Addicks EM. Chronic experimental glaucoma in primates. II. Effect of extended intraocular pressure elevation on optic nerve head and axonal transport. Invest Ophthalmol Vis Sci 1980; 19: 137–152. Quigley H, Anderson DR. The dynamics and location of axonal transport blockade by acute intraocular pressure elevation in primate optic nerve. Invest Ophthalmol 1976; 15: 606–616. Pease ME, McKinnon SJ, Quigley HA, KerriganBaumrind LA, Zack DJ. Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma. Invest Ophthalmol Vis Sci 2000; 41: 764–774. Quigley HA, McKinnon SJ, Zack DJ, Pease ME, Kerrigan-Baumrind LA, Kerrigan DF, Mitchell RS. Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats. Invest Ophthalmol Vis Sci 2000; 41: 3460–3466. Fechtner RD, Weinreb RN. Mechanisms of optic nerve damage in primary open angle glaucoma. Surv Ophthalmol 1994; 39: 23–42. Rudzinski M, Wong TP, Saragovi HU. Changes in retinal expression of neurotrophins and neurotrophin receptors induced by ocular hypertension. J Neurobiol 2004; 58: 341–354. Burgoyne CF, Downs JC. Premise and prediction: how optic nerve head biomechanics underlies the susceptibility and clinical behavior of the aged optic nerve head. J Glaucoma 2008; 17: 318– 328. Geijer C, Bill A. Effects of raised intraocular pressure on retinal, prelaminar, laminar and retrolaminar optic nerve blood flow in monkeys. Invest Ophthalmol Vis Sci 1979; 18: 1030–1042. Kiel JW, van Heuven WA. Ocular perfusion pressure and choroidal blood flow in the rabbit. Invest Ophthalmol Vis Sci 1995; 36: 579–585. Flammer J, Orgul S, Costa VP, Orzalesi N, Krieglstein GK, Serra LM, Renard JP et al. The impact of ocular blood flow in glaucoma. Prog Retin Eye Res 2002; 21: 359–393. Emre M, Orgul S, Gugleta K, Flammer J. Ocular blood flow alteration in glaucoma is related to systemic vascular dysregulation. Br J Ophthalmol 2004; 88: 662–666. Kawai SI, Vora S, Das S, Gachie E, Becker B, Neufeld AH. Modeling of risk factors for the degeneration of retinal ganglion cells after ischemia/reperfusion in rats: effects of age, caloric restriction, diabetes, pigmentation and glaucoma. FASEB J 2001; 15: 1285–1287. Osborne NN, Melena J, Chidlow G, Wood JP. A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: possible implication for the treatment of glaucoma. Br J Ophthalmol 2001; 85: 1252–1259. Dielemans I, Vingerling JR, Wolfs RC, Hofman A, Grobbee DE, de Jong PT. The prevalence of primary open-angle glaucoma in a populationbased study in The Netherlands. The Rotterdam Study. Ophthalmology 1994; 101: 1851–1855. Cockburn DM. Diagnosis and management of open angle glaucoma: suggested guidelines for optometrists. Clin Exp Optom 2000; 83: 119–127. Kern TS, Barber AJ. Retinal ganglion cells in diabetes. J Physiol 2008; 586: 4401–4408.

43. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241: 2035–2038. 44. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979; 59: 8–13. 45. Liew G, Wang JJ. Retinal vascular signs in diabetes and hypertension–review. Arq Bras Endocrinol Metabol 2007; 51: 352–362. 46. Armstrong JR, Daily RK, Dobson HL, Girard LJ. The incidence of glaucoma in diabetes mellitus. A comparison with the incidence of glaucoma in the general population. Am J Ophthalmol 1960; 50: 55–63. 47. Becker B. Diabetes mellitus and primary openangle glaucoma. The XXVII Edward Jackson Memorial Lecture. Am J Ophthalmol 1971; 1: 1–16. 48. Tielsch JM, Katz J, Quigley HA, Javitt JC, Sommer A. Diabetes, intraocular pressure, and primary open-angle glaucoma in the Baltimore Eye Survey. Ophthalmology 1995; 102: 48–53. 49. Klein BE, Klein R, Moss SE. Intraocular pressure in diabetic persons. Ophthalmology 1984; 91: 1356–1360. 50. Klein BE, Klein R, Jensen SC. Open-angle glaucoma and older-onset diabetes. The Beaver Dam Eye Study. Ophthalmology 1994; 101: 1173–1177. 51. Kawase K, Tomidokoro A, Araie M, Iwase A, Yamamoto T. Ocular and systemic factors related to intraocular pressure in Japanese adults: the Tajimi study. Br J Ophthalmol 2008; 92: 1175–1179. 52. Ellis JD, Evans JM, Ruta DA, Baines PS, Leese G, MacDonald TM, Morris AD. Glaucoma incidence in an unselected cohort of diabetic patients: is diabetes mellitus a risk factor for glaucoma? DARTS/MEMO collaboration. Diabetes Audit and Research in Tayside Study. Medicines Monitoring Unit. Br J Ophthalmol 2000; 84: 1218–1224. 53. Oshitari T, Fujimoto N, Hanawa K, Adachi-Usami E, Roy S. Effect of chronic hyperglycemia on intraocular pressure in patients with diabetes. Am J Ophthalmol 2007; 143: 363–365. 54. Bankes JL. Ocular tension and diabetes mellitus. Br J Ophthalmol 1967; 51: 557–561. 55. Dielemans I, de Jong PT, Stolk R, Vingerling JR, Grobbee DE, Hofman A. Primary open-angle glaucoma, intraocular pressure, and diabetes mellitus in the general elderly population. The Rotterdam Study. Ophthalmology 1996; 103: 1271– 1275. 56. Mitchell P, Smith W, Chey T, Healey PR. Openangle glaucoma and diabetes: the Blue Mountains eye study, Australia. Ophthalmology 1997; 104: 712–718. 57. Ozcura F, Aydin S. Is diabetes mellitus a risk factor or a protector for primary open angle glaucoma? Med Hypotheses 2007; 69: 233–234. 58. Kahn HA, Leibowitz HM, Ganley JP, Kini MM, Colton T, Nickerson RS, Dawber TR. The Framingham Eye Study. II. Association of ophthalmic pathology with single variables previously measured in the Framingham Heart Study. Am J Epidemiol 1977; 106: 33–41. 59. Kahn HA, Milton RC. Alternative definitions of open-angle glaucoma. Effect on prevalence and associations in the Framingham eye study. Arch Ophthalmol 1980; 98: 2172–2177. 60. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary



61.

62.

63. 64.

65.

66.

67.

68.

69.

70.

71.

72.

73.

74.

75.

76.

77.

open-angle glaucoma. Arch Ophthalmol 2002; 120: 714–720; discussion 829–730. Coleman AL, Miglior S. Risk factors for glaucoma onset and progression. Surv Ophthalmol 2008; 53 Suppl1: S3–S10. Gordon MO, Beiser JA, Kass MA. Is a history of diabetes mellitus protective against developing primary open-angle glaucoma? Arch Ophthalmol 2008; 126: 280–281. Wolter JR. Diabetic retinopathy. Am J Ophthalmol 1961; 51: 1123–1141. Hammes HP, Federoff HJ, Brownlee M. Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes. Mol Med 1995; 1: 527–534. Ino-Ue M, Zhang L, Naka H, Kuriyama H, Yamamoto M. Polyol metabolism of retrograde axonal transport in diabetic rat large optic nerve fiber. Invest Ophthalmol Vis Sci 2000; 41: 4055–4058. Nakamura M, Kanamori A, Negi A. Diabetes mellitus as a risk factor for glaucomatous optic neuropathy. Ophthalmologica 2005; 219: 1–10. Asnaghi V, Gerhardinger C, Hoehn T, Adeboje A, Lorenzi M. A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes 2003; 52: 506–511. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 1998; 102: 783–791. Kanamori A, Nakamura M, Mukuno H, Maeda H, Negi A. Diabetes has an additive effect on neural apoptosis in rat retina with chronically elevated intraocular pressure. Curr Eye Res 2004; 28: 47– 54. Russell JW, Sullivan KA, Windebank AJ, Herrmann DN, Feldman EL. Neurons undergo apoptosis in animal and cell culture models of diabetes. Neurobiol Dis 1999; 6: 347–363. Oshitari T, Roy S. Diabetes: a potential enhancer of retinal injury in rat retinas. Neurosci Lett 2005; 390: 25–30. Sima AA, Zhang WX, Cherian PV, Chakrabarti S. Impaired visual evoked potential and primary axonopathy of the optic nerve in the diabetic BB/W-rat. Diabetologia 1992; 35: 602–607. Zeng XX, Ng YK, Ling EA. Neuronal and microglial response in the retina of streptozotocininduced diabetic rats. Vis Neurosci 2000; 17: 463–471. Bui BV, Loeliger M, Thomas M, Vingrys AJ, Rees SM, Nguyen CT, He Z et al. Investigating structural and biochemical correlates of ganglion cell dysfunction in streptozotocin-induced diabetic rats. Exp Eye Res 2009; 88: 1076–1083. Sugimoto M, Sasoh M, Ido M, Wakitani Y, Takahashi C, Uji Y. Detection of early diabetic change with optical coherence tomography in type 2 diabetes mellitus patients without retinopathy. Ophthalmologica 2005; 219: 379–385. van Dijk HW, Kok PH, Garvin M, Sonka M, Devries JH, Michels RP, van Velthoven ME et al. Selective loss of inner retinal layer thickness in type 1 diabetic patients with minimal diabetic retinopathy. Invest Ophthalmol Vis Sci 2009; 50: 3404–3409. van Dijk HW, Verbraak FD, Kok PH, Garvin MK, Sonka M, Lee K, Devries JH et al. Decreased retinal ganglion cell layer thickness in type 1

78.

79.

80.

81.

82.

83.

84.

85.

86.

87.

88.

89.

90.

91.

92.

93.

94.

diabetic patients. Invest Ophthalmol Vis Sci 2010; 51: 3660–3665. Weinreb RN, Shakiba S, Sample PA, Shahrokni S, van Horn S, Garden VS, Asawaphureekorn S et al. Association between quantitative nerve fiber layer measurement and visual field loss in glaucoma. Am J Ophthalmol 1995; 120: 732–738. Quigley HA, Hohman RM, Addicks EM, Massof RW, Green WR. Morphologic changes in the lamina cribrosa correlated with neural loss in open-angle glaucoma. Am J Ophthalmol 1983; 95: 673–691. Phipps JA, Fletcher EL, Vingrys AJ. Paired-flash identification of rod and cone dysfunction in the diabetic rat. Invest Ophthalmol Vis Sci 2004; 45: 4592–4600. Ishii H, Koya D, King GL. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med 1998; 76: 21–31. King GL, Shiba T, Oliver J, Inoguchi T, Bursell SE. Cellular and molecular abnormalities in the vascular endothelium of diabetes mellitus. Annu Rev Med 1994; 45: 179–188. Yee P, Weymouth AE, Fletcher EL, Vingrys AJ. A role for omega-3 polyunsaturated fatty acid supplements in diabetic neuropathy. Invest Ophthalmol Vis Sci 2010; 51: 1755–1764. Bui BV, Armitage JA, Vingrys AJ. Extraction and modelling of oscillatory potentials. Doc Ophthalmol 2002; 104: 17–36. Forte JD, Bui BV, Vingrys AJ. Wavelet analysis reveals dynamics of rat oscillatory potentials. J Neurosci Methods 2008; 169: 191–200. Coupland SG. A comparison of oscillatory potential and pattern electroretinogram measures in diabetic retinopathy. Doc Ophthalmol 1987; 66: 207–218. Bresnick GH, Palta M. Oscillatory potential amplitudes. Relation to severity of diabetic retinopathy. Arch Ophthalmol 1987; 105: 929–933. Holopigian K, Seiple W, Lorenzo M, Carr R. A comparison of photopic and scotopic electroretinographic changes in early diabetic retinopathy. Invest Ophthalmol Vis Sci 1992; 33: 2773–2780. Roecker EB, Pulos E, Bresnick GH, Severns M. Characterization of the electroretinographic scotopic B-wave amplitude in diabetic and normal subjects. Invest Ophthalmol Vis Sci 1992; 33: 1575–1583. Uccioli L, Parisi V, Monticone G, Parisi L, Durola L, Pernini C, Neuschuler R et al. Electrophysiological assessment of visual function in newlydiagnosed IDDM patients. Diabetologia 1995; 38: 804–808. Sakai H, Tani Y, Shirasawa E, Shirao Y, Kawasaki K. Development of electroretinographic alterations in streptozotocin-induced diabetes in rats. Ophthalmic Res 1995; 27: 57–63. Ramsey DJ, Ripps H, Qian H. An electrophysiological study of retinal function in the diabetic female rat. Invest Ophthalmol Vis Sci 2006; 47: 5116–5124. Kizawa J, Machida S, Kobayashi T, Gotoh Y, Kurosaka D. Changes of oscillatory potentials and photopic negative response in patients with early diabetic retinopathy. Jpn J Ophthalmol 2006; 50: 367–373. Shinoda K, Rejdak R, Schuettauf F, Blatsios G, Volker M, Tanimoto N, Olcay T et al. Early elec-


95.

96.

97.

98.

99.

100.

101.

102.

103.

104.

105.

106.

107.

108.

109.

110.

111.

troretinographic features of streptozotocininduced diabetic retinopathy. Clin Experiment Ophthalmol 2007; 35: 847–854. Dong CJ, Hare WA. GABAc feedback pathway modulates the amplitude and kinetics of ERG b-wave in a mammalian retina in vivo. Vision Res 2002; 42: 1081–1087. Wachtmeister L, Dowling JE. The oscillatory potentials of the mudpuppy retina. Invest Ophthalmol Vis Sci 1978; 17: 1176–1188. Matthews GP, Crane WG, Sandberg MA. Effects of 2-amino-4-phosphonobutyric acid (APB) and glycine on the oscillatory potentials of the rat electroretinogram. Exp Eye Res 1989; 49: 777–787. Wachtmeister L. Further studies of the chemical sensitivity of the oscillatory potentials of the electroretinogram (ERG) I. GABA- and glycine antagonists. Acta Ophthalmol (Copenh) 1980; 58: 712–725. Gastinger MJ, Singh RS, Barber AJ. Loss of cholinergic and dopaminergic amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas. Invest Ophthalmol Vis Sci 2006; 47: 3143–3150. Li X, Sun X, Hu Y, Huang J, Zhang H. Electroretinographic oscillatory potentials in diabetic retinopathy. An analysis in the domains of time and frequency. Doc Ophthalmol 1992; 81: 173–179. Van der Torren K, Groeneweg G, van Lith G. Measuring oscillatory potentials: Fourier analysis. Doc Ophthalmol 1988; 69: 153–159. Layton CJ, Safa R, Osborne NN. Oscillatory potentials and the b-Wave: partial masking and interdependence in dark adaptation and diabetes in the rat. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1335–1345. Weisinger H, Vingrys A, Sinclair A. Electrodiagnostic methods in vision, Part 3 Clinical electrophysiology. Clin Exp Optom 1996; 79: 131–143. Parisi V, Uccioli L. Visual electrophysiological responses in persons with type 1 diabetes. Diabetes Metab Res Rev 2001; 17: 12–18. Viswanathan S, Frishman LJ, Robson JG, Harwerth RS, Smith EL 3rd. The photopic negative response of the macaque electroretinogram: reduction by experimental glaucoma. Invest Ophthalmol Vis Sci 1999; 40: 1124–1136. Viswanathan S, Frishman LJ, Robson JG. The uniform field and pattern ERG in macaques with experimental glaucoma: removal of spiking activity. Invest Ophthalmol Vis Sci 2000; 41: 2797– 2810. Rangaswamy NV, Frishman LJ, Dorotheo EU, Schiffman JS, Bahrani HM, Tang RA. Photopic ERGs in patients with optic neuropathies: comparison with primate ERGs after pharmacologic blockade of inner retina. Invest Ophthalmol Vis Sci 2004; 45: 3827–3837. Rangaswamy NV, Zhou W, Harwerth RS, Frishman LJ. Effect of experimental glaucoma in primates on oscillatory potentials of the slowsequence mfERG. Invest Ophthalmol Vis Sci 2006; 47: 753–767. Sieving PA, Frishman LJ, Steinberg RH. Scotopic threshold response of proximal retina in cat. J Neurophysiol 1986; 56: 1049–1061. Sieving PA, Nino C. Scotopic threshold response (STR) of the human electroretinogram. Invest Ophthalmol Vis Sci 1988; 29: 1608–1614. Frishman LJ, Shen FF, Du L, Robson JG, Harwerth RS, Smith EL 3rd, Carter-Dawson L et al.


19


112.

113.

114.

115.

116.

117.

118.

119.

120.

121.

122.

123.

124.

125.

126.

127.

128.

129.

The scotopic electroretinogram of macaque after retinal ganglion cell loss from experimental glaucoma. Invest Ophthalmol Vis Sci 1996; 37: 125–141. Frishman LJ, Steinberg RH. Intraretinal analysis of the threshold dark-adapted ERG of cat retina. J Neurophysiol 1989; 61: 1221–1232. Bui BV, Fortune B. Ganglion cell contributions to the rat full-field electroretinogram. J Physiol 2004; 555: 153–173. Saszik SM, Robson JG, Frishman LJ. The scotopic threshold response of the dark-adapted electroretinogram of the mouse. J Physiol 2002; 543: 899–916. He Z, Bui BV, Vingrys AJ. The rate of functional recovery from acute IOP elevation. Invest Ophthalmol Vis Sci 2006; 47: 4872–4880. Fortune B, Bui BV, Morrison JC, Johnson EC, Dong J, Cepurna WO, Jia L et al. Selective ganglion cell functional loss in rats with experimental glaucoma. Invest Ophthalmol Vis Sci 2004; 45: 1854–1862. Kohzaki K, Vingrys AJ, Bui BV. Early inner retinal dysfunction in streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci 2008; 49: 3595–3604. Vesti E, Trick GL. Diabetes can alter the interpretation of visual dysfunction in ocular hypertension. Ophthalmology 1996; 103: 1419–1425. Quigley HA, Enger C, Katz J, Sommer A, Scott R, Gilbert D. Risk factors for the development of glaucomatous visual field loss in ocular hypertension. Arch Ophthalmol 1994; 112: 644–649. Casson RJ, Chidlow G, Wood JP, Osborne NN. The effect of hyperglycemia on experimental retinal ischemia. Arch Ophthalmol 2004; 122: 361– 366. Holman MC, Chidlow G, Wood JP, Casson RJ. The effect of hyperglycemia on hypoperfusioninduced injury. Invest Ophthalmol Vis Sci 2010; 51: 2197–2207. Kim C, Kim TW. Comparison of risk factors for bilateral and unilateral eye involvement in normal-tension glaucoma. Invest Ophthalmol Vis Sci 2009; 50: 1215–1220. Hedrick CC, Thorpe SR, Fu MX, Harper CM, Yoo J, Kim SM, Wong H et al. Glycation impairs highdensity lipoprotein function. Diabetologia 2000; 43: 312–320. Huang YS, Horrobin DF, Manku MS, Mitchell J, Ryan MA. Tissue phospholipid fatty acid composition in the diabetic rat. Lipids 1984; 19: 367– 370. Chattopadhyay J, Thompson EW, Schmid HH. Nonesterified fatty acids in normal and diabetic rat sciatic nerve. Lipids 1992; 27: 513–517. Ruiz-Gutierrez V, Stiefel P, Villar J, Garcia-Donas MA, Acosta D, Carneado J. Cell membrane fatty acid composition in type 1 (insulin-dependent) diabetic patients: relationship with sodium transport abnormalities and metabolic control. Diabetologia 1993; 36: 850–856. Ghebremeskel K, Thomas B, Lowy C, Min Y, Crawford MA. Type 1 diabetes compromises plasma arachidonic and docosahexaenoic acids in newborn babies. Lipids 2004; 39: 335–342. de Gomez Dumm IN, Montenegro S, Tarrés MC, Martinez SM, Igal RA. Early lipid alterations in spontaneously diabetic rats. Acta Physiol Pharmacol Ther Latinoam 1998; 48: 228–234. Nguyen CT, Vingrys AJ, Bui BV. Dietary omega-3 fatty acids and ganglion cell function. Invest Ophthalmol Vis Sci 2008; 49: 3586–3594.


20

130. Weisinger HS, Vingrys AJ, Bui BV, Sinclair AJ. Effects of dietary n-3 fatty acid deficiency and repletion in the guinea pig retina. Invest Ophthalmol Vis Sci 1999; 40: 327–338. 131. Bazan NG. Homeostatic regulation of photoreceptor cell integrity: significance of the potent mediator neuroprotectin D1 biosynthesized from docosahexaenoic acid: the Proctor Lecture. Invest Ophthalmol Vis Sci 2007; 48: 4866–4881; biography 4864–4865. 132. Bazan NG. Omega-3 fatty acids, proinflammatory signaling and neuroprotection. Curr Opin Clin Nutr Metab Care 2007; 10: 136–141. 133. Krauss RM, Siri PW. Dyslipidemia in type 2 diabetes. Med Clin North Am 2004; 88: 897–909. 134. Glatz JF, Luiken JJ, Bonen A. Membrane fatty acid transporters as regulators of lipid metabolism: implications for metabolic disease. Physiol Rev 2010; 90: 367–417. 135. Tapiero H, Ba GN, Couvreur P, Tew KD. Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies. Biomed Pharmacother 2002; 56: 215–222. 136. Calder PC. Effects of fatty acids and dietary lipids on cells of the immune system. Proc Nutr Soc 1996; 55: 127–150. 137. Tezel G, Wax MB. The immune system and glaucoma. Curr Opin Ophthalmol 2004; 15: 80–84. 138. SanGiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Res 2005; 24: 87–138. 139. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch’s membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 2001; 20: 705–732. 140. Tang J, Zhu XW, Lust WD, Kern TS. Retina accumulates more glucose than does the embryologically similar cerebral cortex in diabetic rats. Diabetologia 2000; 43: 1417–1423. 141. Kim DI, Lim SK, Park MJ, Han HJ, Kim GY, Park SH. The involvement of phosphatidylinositol 3-kinase/Akt signaling in high glucose-induced downregulation of GLUT-1 expression in ARPE cells. Life Sci 2007; 80: 626–632. 142. Kong GY, Van Bergen NJ, Trounce IA, Crowston JG. Mitochondrial dysfunction and glaucoma. J Glaucoma 2009; 18: 93–100. 143. Lin J, Feng Y, Hagen F, Hammes H-P. Cellular crosstalk under hyperglycemic stress: the diabetic retina as a paradigm. Internat Congress Series 2004; 1262: 156–159. 144. Su EN, Alder VA, Yu DY, Yu PK, Cringle SJ, Yogesan K. Continued progression of retinopathy despite spontaneous recovery to normoglycemia in a long-term study of streptozotocininduced diabetes in rats. Graefes Arch Clin Exp Ophthalmol 2000; 238: 163–173. 145. Speiser P, Gittelsohn AM, Patz A. Studies on diabetic retinopathy. 3. Influence of diabetes on intramural pericytes. Arch Ophthalmol 1968; 80: 332–337. 146. Hammes HP. Pericytes and the pathogenesis of diabetic retinopathy. Horm Metab Res 2005; 37 Suppl 1: 39–43. 147. Aiello LP, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL 3rd, Klein R. Diabetic retinopathy. Diabetes Care 1998; 21: 143–156.

148. Harhaj NS, Felinski EA, Wolpert EB, Sundstrom JM, Gardner TW, Antonetti DA. VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Invest Ophthalmol Vis Sci 2006; 47: 5106–5115. 149. Xu X, Zhu Q, Xia X, Zhang S, Gu Q, Luo D. Blood-retinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocin-induced diabetic rats. Curr Eye Res 2004; 28: 251– 256. 150. Sone H, Kawakami Y, Okuda Y, Sekine Y, Honmura S, Matsuo K, Segawa T et al. Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes. Diabetologia 1997; 40: 726– 730. 151. Ambati J, Chalam KV, Chawla DK, D’Angio CT, Guillet EG, Rose SJ, Vanderlinde RE et al. Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol 1997; 115: 1161– 1166. 152. Aiello LP. Angiogenic pathways in diabetic retinopathy. N Engl J Med 2005; 353: 839–841. 153. Sone H, Okuda Y, Kawakami Y, Hanatani M, Suzuki H, Kozawa T, Honmura S et al. Vascular endothelial growth factor level in aqueous humor of diabetic patients with rubeotic glaucoma is markedly elevated. Diabetes Care 1996; 19: 1306–1307. 154. Higashi S, Clermont AC, Dhir V, Bursell SE. Reversibility of retinal flow abnormalities is disease-duration dependent in diabetic rats. Diabetes 1998; 47: 653–659. 155. Clermont AC, Bursell SE. Retinal blood flow in diabetes. Microcirculation 2007; 14: 49–61. 156. Bursell SE, Clermont AC, Kinsley BT, Simonson DC, Aiello LM, Wolpert HA. Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. Invest Ophthalmol Vis Sci 1996; 37: 886–897. 157. Wangsa-Wirawan ND, Linsenmeier RA. Retinal oxygen: fundamental and clinical aspects. Arch Ophthalmol 2003; 121: 547–557. 158. Yu PK, Yu DY, Alder VA, Su EN, Cringle SJ. Intracellular structures of retinal vascular endothelium in normal and early diabetic rats. Aust N Z J Ophthalmol 1998; 26 Suppl 1: S53–55. 159. Cringle SJ, Yu DY, Alder VA, Su EN. Retinal blood flow by hydrogen clearance polarography in the streptozotocin-induced diabetic rat. Invest Ophthalmol Vis Sci 1993; 34: 1716–1721. 160. Pemp B, Schmetterer L. Ocular blood flow in diabetes and age-related macular degeneration. Can J Ophthalmol 2008; 43: 295–301. 161. Bek T, Hajari J, Jeppesen P. Interaction between flicker-induced vasodilatation and pressure autoregulation in early retinopathy of type 2 diabetes. Graefes Arch Clin Exp Ophthalmol 2008; 246: 763– 769. 162. Toda N, Nakanishi-Toda M. Nitric oxide: ocular blood flow, glaucoma and diabetic retinopathy. Prog Retin Eye Res 2007; 26: 205–238. 163. Flammer J, Mozaffarieh M. Autoregulation, a balancing act between supply and demand. Can J Ophthalmol 2008; 43: 317–321. 164. Wilkinson-Berka JL. Vasoactive factors and diabetic retinopathy: vascular endothelial growth



165.

166.

167.

168.

169.

170.

171.

172.

173.

174.

175.

176.

177.

178.

179.

180.

factor, cycoloxygenase-2 and nitric oxide. Curr Pharm Des 2004; 10: 3331–3348. Levy AP, Levy NS, Goldberg MA. Posttranscriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem 1996; 271: 2746–2753. Arjamaa O, Nikinmaa M. Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. Exp Eye Res 2006; 83: 473–483. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604–4613. Danylkova NO, Pomeranz HD, Alcala SR, McLoon LK. Histological and morphometric evaluation of transient retinal and optic nerve ischemia in rat. Brain Res 2006; 1096: 20– 29. Tezel G, Wax MB. Hypoxia-inducible factor 1alpha in the glaucomatous retina and optic nerve head. Arch Ophthalmol 2004; 122: 1348– 1356. Arden GB, Sidman RL, Arap W, Schlingemann RO. Spare the rod and spoil the eye. Br J Ophthalmol 2005; 89: 764–769. Arden GB. The absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible treatment. Br J Ophthalmol 2001; 85: 366–370. de Gooyer TE, Stevenson KA, Humphries P, Simpson DA, Gardiner TA, Stitt AW. Retinopathy is reduced during experimental diabetes in a mouse model of outer retinal degeneration. Invest Ophthalmol Vis Sci 2006; 47: 5561– 5568. Yu DY, Cringle SJ, Su EN, Yu PK, Jerums G, Cooper ME. Pathogenesis and intervention strategies in diabetic retinopathy. Clin Experiment Ophthalmol 2001; 29: 164–166. Van den Enden MK, Nyengaard JR, Ostrow E, Burgan JH, Williamson JR. Elevated glucose levels increase retinal glycolysis and sorbitol pathway metabolism. Implications for diabetic retinopathy. Invest Ophthalmol Vis Sci 1995; 36: 1675–1685. Soulis T, Thallas V, Youssef S, Gilbert RE, McWilliam BG, Murray-McIntosh RP, Cooper ME. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 1997; 40: 619–628. Fox TE, Han X, Kelly S, Merrill AH 2nd, Martin RE, Anderson RE, Gardner TW et al. Diabetes alters sphingolipid metabolism in the retina: a potential mechanism of cell death in diabetic retinopathy. Diabetes 2006; 55: 3573–3580. Yabe-Nishimura C. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol Rev 1998; 50: 21–33. Tomlinson DR. Mitogen-activated protein kinases as glucose transducers for diabetic complications. Diabetologia 1999; 42: 1271–1281. Neufeld AH, Hernandez MR, Gonzalez M. Nitric oxide synthase in the human glaucomatous optic nerve head. Arch Ophthalmol 1997; 115: 497–503. Engerman RL, Kern TS. Experimental galactosemia produces diabetic-like retinopathy. Diabetes 1984; 33: 97–100.

181. Schmetterer L, Wolzt M. Ocular blood flow and associated functional deviations in diabetic retinopathy. Diabetologia 1999; 42: 387–405. 182. Ellis EA, Grant MB, Murray FT, Wachowski MB, Guberski DL, Kubilis PS, Lutty GA. Increased NADH oxidase activity in the retina of the BBZ/ Wor diabetic rat. Free Radic Biol Med 1998; 24: 111–120. 183. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, Nyengaard JR et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993; 42: 801–813. 184. Ho EC, Lam KS, Chen YS, Yip JC, Arvindakshan M, Yamagishi S, Yagihashi S et al. Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage. Diabetes 2006; 55: 1946–1953. 185. Winkler BS, Arnold MJ, Brassell MA, Sliter DR. Glucose dependence of glycolysis, hexose monophosphate shunt activity, energy status, and the polyol pathway in retinas isolated from normal (nondiabetic) rats. Invest Ophthalmol Vis Sci 1997; 38: 62–71. 186. Diederen RM, Starnes CA, Berkowitz BA, Winkler BS. Re-examining the hyperglycemic pseudohypoxia hypothesis of diabetic oculopathy. Invest Ophthalmol Vis Sci 2006; 47: 2726– 2731. 187. Tilton RG. Diabetic vascular dysfunction: links to glucose-induced reductive stress and VEGF. Microsc Res Tech 2002; 57: 390–407. 188. Alexander JP, Acott TS. Involvement of protein kinase C in TNFalpha regulation of trabecular matrix metalloproteinases and TIMPs. Invest Ophthalmol Vis Sci 2001; 42: 2831–2838. 189. Khurana RN, Deng PF, Epstein DL, Vasantha Rao P. The role of protein kinase C in modulation of aqueous humor outflow facility. Exp Eye Res 2003; 76: 39–47. 190. Sivak JM, Fini ME. MMPs in the eye: emerging roles for matrix metalloproteinases in ocular physiology. Prog Retin Eye Res 2002; 21: 1–14. 191. Kuehn MH, Fingert JH, Kwon YH. Retinal ganglion cell death in glaucoma: mechanisms and neuroprotective strategies. Ophthalmol Clin North Am 2005; 18: 383–395, vi. 192. Else PL, Wu BJ. What role for membranes in determining the higher sodium pump molecular activity of mammals compared to ectotherms? J Comp Physiol B 1999; 169: 296–302. 193. Gerbi A, Zerouga M, Debray M, Durand G, Chanez C, Bourre JM. Effect of dietary alphalinolenic acid on functional characteristic of Na+/K(+)-ATPase isoenzymes in whole brain membranes of weaned rats. Biochim Biophys Acta 1993; 1165: 291–298. 194. Baylor DA, Matthews G, Nunn BJ. Location and function of voltage-sensitive conductances in retinal rods of the salamander, Ambystoma tigrinum. J Physiol 1984; 354: 203–223. 195. Baylor DA, Lamb TD, Yau KW. The membrane current of single rod outer segments. J Physiol 1979; 288: 589–611. 196. Yau KW, Lamb TD, Matthews G, Baylor DA. Current fluctuations across single rod outer segments. Vision Res 1979; 19: 387–390. 197. Phipps JA, Yee P, Fletcher EL, Vingrys AJ. Rod photoreceptor dysfunction in diabetes: activa-


198.

199.

200.

201.

202.

203.

204.

205.

206.

207.

208.

209.

210.

211.

212.

213.

tion, deactivation, and dark adaptation. Invest Ophthalmol Vis Sci 2006; 47: 3187–3194. MacGregor LC, Matschinsky FM. Altered retinal metabolism in diabetes. II. Measurement of sodium-potassium ATPase and total sodium and potassium in individual retinal layers. J Biol Chem 1986; 261: 4052–4058. Hatou S, Yamada M, Mochizuki H, Nishida T. Role of protein kinase C in regulation of Na+and K +-dependent ATPase activity and pump function in corneal endothelial cells. Jpn J Ophthalmol 2009; 53: 235–242. Ames A, 3rd, Li YY, Heher EC, Kimble CR. Energy metabolism of rabbit retina as related to function: high cost of Na+ transport. J Neurosci 1992; 12: 840–853. Roufail E, Soulis T, Boel E, Cooper ME, Rees S. Depletion of nitric oxide synthase-containing neurons in the diabetic retina: reversal by aminoguanidine. Diabetologia 1998; 41: 1419–1425. Li Q, Zemel E, Miller B, Perlman I. NADPH diaphorase activity in the rat retina during the early stages of experimental diabetes. Graefes Arch Clin Exp Ophthalmol 2003; 241: 747–756. Doganay S, Evereklioglu C, Er H, Turkoz Y, Sevinc A, Mehmet N, Savli H. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye (Lond) 2002; 16: 163– 170. Ozden S, Tatlipinar S, Bicer N, Yaylali V, Yildirim C, Ozbay D, Guner G. Basal serum nitric oxide levels in patients with type 2 diabetes mellitus and different stages of retinopathy. Can J Ophthalmol 2003; 38: 393–396. Abu El-Asrar AM, Desmet S, Meersschaert A, Dralands L, Missotten L, Geboes K. Expression of the inducible isoform of nitric oxide synthase in the retinas of human subjects with diabetes mellitus. Am J Ophthalmol 2001; 132: 551–556. Kowluru RA. Diabetes-induced elevations in retinal oxidative stress, protein kinase C and nitric oxide are interrelated. Acta Diabetol 2001; 38: 179–185. Goto R, Doi M, Ma N, Semba R, Uji Y. Contribution of nitric oxide-producing cells in normal and diabetic rat retina. Jpn J Ophthalmol 2005; 49: 363–370. Fletcher EL, Phipps JA, Ward MM, Puthussery T, Wilkinson-Berka JL. Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy. Curr Pharm Des 2007; 13: 2699– 2712. Kawasaki A, Otori Y, Barnstable CJ. Müller cell protection of rat retinal ganglion cells from glutamate and nitric oxide neurotoxicity. Invest Ophthalmol Vis Sci 2000; 41: 3444–3450. Kalloniatis M, Tomisich G. Amino acid neurochemistry of the vertebrate retina. Prog Retin Eye Res 1999; 18: 811–866. Nicolela MT, Hnik P, Drance SM. Scanning laser Doppler flowmeter study of retinal and optic disk blood flow in glaucomatous patients. Am J Ophthalmol 1996; 122: 775–783. Sena DF, Ramchand K, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev 2010; 2: CD006539. Neufeld AH. Pharmacologic neuroprotection with an inhibitor of nitric oxide synthase for the treatment of glaucoma. Brain Res Bull 2004; 62: 455–459.


21


214. Vidal L, Diaz F, Villena A, Moreno M, Campos JG, de Vargas IP. Nitric oxide synthase in retina and optic nerve head of rat with increased intraocular pressure and effect of timolol. Brain Res Bull 2006; 70: 406–413. 215. Chiou GC. Review: effects of nitric oxide on eye diseases and their treatment. J Ocul Pharmacol Ther 2001; 17: 189–198. 216. Tomlinson DR, Fernyhough P, Diemel LT. Neurotrophins and peripheral neuropathy. Philos Trans R Soc Lond B Biol Sci 1996; 351: 455–462. 217. Zhang L, Ino-ue M, Dong K, Yamamoto M. Retrograde axonal transport impairment of largeand medium-sized retinal ganglion cells in diabetic rat. Curr Eye Res 2000; 20: 131–136. 218. Apfel SC. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int Rev Neurobiol 2002; 50: 393–413. 219. Rodriguez-Pena A, Botana M, Gonzalez M, Requejo F. Expression of neurotrophins and their receptors in sciatic nerve of experimentally diabetic rats. Neurosci Lett 1995; 200: 37–40. 220. Fernyhough P, Diemel LT, Tomlinson DR. Target tissue production and axonal transport of neurotrophin-3 are reduced in streptozotocindiabetic rats. Diabetologia 1998; 41: 300–306. 221. Seigel GM, Lupien SB, Campbell LM, Ishii DN. Systemic IGF-I treatment inhibits cell death in diabetic rat retina. J Diabetes Complications 2006; 20: 196–204. 222. Seki M, Tanaka T, Nawa H, Usui T, Fukuchi T, Ikeda K, Abe H, Takei N. Involvement of brainderived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells. Diabetes 2004; 53: 2412–2419. 223. Krabbe KS, Nielsen AR, Krogh-Madsen R, Plomgaard P, Rasmussen P, Erikstrup C, Fischer CP et al. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 2007; 50: 431– 438. 224. Minckler DS, Bunt AH, Johanson GW. Orthograde and retrograde axoplasmic transport during acute ocular hypertension in the monkey. Invest Ophthalmol Vis Sci 1977; 16: 426–441. 225. Quigley HA, Anderson DR. Distribution of axonal transport blockade by acute intraocular pressure elevation in the primate optic nerve head. Invest Ophthalmol Vis Sci 1977; 16: 640–644. 226. Balaratnasingam C, Morgan WH, Bass L, Matich G, Cringle SJ, Yu DY. Axonal transport and cytoskeletal changes in the laminar regions after elevated intraocular pressure. Invest Ophthalmol Vis Sci 2007; 48: 3632–3644. 227. Abu El-Asrar AM, Van den Steen PE, Al-Amro SA, Missotten L, Opdenakker G, Geboes K. Expression of angiogenic and fibrogenic factors in proliferative vitreoretinal disorders. Int Ophthalmol 2007; 27: 11–22. 228. Kuiper EJ, Witmer AN, Klaassen I, Oliver N, Goldschmeding R, Schlingemann RO. Differential expression of connective tissue growth factor in microglia and pericytes in the human diabetic retina. Br J Ophthalmol 2004; 88: 1082–1087. 229. Tikellis C, Cooper ME, Twigg SM, Burns WC, Tolcos M. Connective tissue growth factor is up-regulated in the diabetic retina: amelioration by angiotensin-converting enzyme inhibition. Endocrinology 2004; 145: 860–866.


22

230. Daniels JT, Schultz GS, Blalock TD, Garrett Q, Grotendorst GR, Dean NM, Khaw PT. Mediation of transforming growth factor-beta(1)-stimulated matrix contraction by fibroblasts: a role for connective tissue growth factor in contractile scarring. Am J Pathol 2003; 163: 2043–2052. 231. Shimo T, Nakanishi T, Nishida T, Asano M, Kanyama M, Kuboki T, Tamatani T et al. Connective tissue growth factor induces the proliferation, migration, and tube formation of vascular endothelial cells in vitro, and angiogenesis in vivo. J Biochem 1999; 126: 137–145. 232. Hishikawa K, Nakaki T, Fujii T. Connective tissue growth factor induces apoptosis via caspase 3 in cultured human aortic smooth muscle cells. Eur J Pharmacol 2000; 392: 19–22. 233. Ho SL, Dogar GF, Wang J, Crean J, Wu QD, Oliver N, Weitz S et al. Elevated aqueous humour tissue inhibitor of matrix metalloproteinase-1 and connective tissue growth factor in pseudoexfoliation syndrome. Br J Ophthalmol 2005; 89: 169–173. 234. Liton PB, Liu X, Challa P, Epstein DL, Gonzalez P. Induction of TGF-beta1 in the trabecular meshwork under cyclic mechanical stress. J Cell Physiol 2005; 205: 364–371. 235. Bellezza AJ, Hart RT, Burgoyne CF. The optic nerve head as a biomechanical structure: initial finite element modeling. Invest Ophthalmol Vis Sci 2000; 41: 2991–3000. 236. Sigal IA, Flanagan JG, Tertinegg I, Ethier CR. Modeling individual-specific human optic nerve head biomechanics. Part I: IOP-induced deformations and influence of geometry. Biomech Model Mechanobiol 2009; 8: 85–98. 237. Downs JC, Roberts MD, Burgoyne CF. Mechanical environment of the optic nerve head in glaucoma. Optom Vis Sci 2008; 85: 425–435. 238. Sigal IA, Ethier CR. Biomechanics of the optic nerve head. Exp Eye Res 2009; 88: 799– 807. 239. Lieth E, Barber AJ, Xu B, Dice C, Ratz MJ, Tanase D, Strother JM. Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Penn State Retina Research Group. Diabetes 1998; 47: 815–820. 240. Newman E, Reichenbach A. The Müller cell: a functional element of the retina. Trends Neurosci 1996; 19: 307–312. 241. Pena JD, Varela HJ, Ricard CS, Hernandez MR. Enhanced tenascin expression associated with reactive astrocytes in human optic nerve heads with primary open angle glaucoma. Exp Eye Res 1999; 68: 29–40. 242. Kobayashi S, Vidal I, Pena JD, Hernandez MR. Expression of neural cell adhesion molecule (NCAM) characterizes a subpopulation of type 1 astrocytes in human optic nerve head. Glia 1997; 20: 262–273. 243. Pena JD, Agapova O, Gabelt BT, Levin LA, Lucarelli MJ, Kaufman PL, Hernandez MR. Increased elastin expression in astrocytes of the lamina cribrosa in response to elevated intraocular pressure. Invest Ophthalmol Vis Sci 2001; 42: 2303–2314. 244. Schori H, Kipnis J, Yoles E, WoldeMussie E, Ruiz G, Wheeler LA, Schwartz M. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc Natl Acad Sci USA 2001; 98: 3398–3403.

245. Wax MB, Tezel G, Yang J, Peng G, Patil RV, Agarwal N, Sappington RM et al. Induced autoimmunity to heat shock proteins elicits glaucomatous loss of retinal ganglion cell neurons via activated T-cell-derived fas-ligand. J Neurosci 2008; 28: 12085–12096. 246. Stasi K, Nagel D, Yang X, Wang RF, Ren L, Podos SM, Mittag T et al. Complement component 1Q (C1Q) upregulation in retina of murine, primate, and human glaucomatous eyes. Invest Ophthalmol Vis Sci 2006; 47: 1024–1029. 247. Elkington AR, Inman CB, Steart PV, Weller RO. The structure of the lamina cribrosa of the human eye: an immunocytochemical and electron microscopical study. Eye (Lond) 1990; 4: 42–57. 248. Sun D, Lye-Barthel M, Masland RH, Jakobs TC. The morphology and spatial arrangement of astrocytes in the optic nerve head of the mouse. J Comp Neurol 2009; 516: 1–19. 249. Varela HJ, Hernandez MR. Astrocyte responses in human optic nerve head with primary openangle glaucoma. J Glaucoma 1997; 6: 303–313. 250. Balaratnasingam C, Morgan WH, Bass L, Ye L, McKnight C, Cringle SJ, Yu DY. Elevated pressure induced astrocyte damage in the optic nerve. Brain Res 2008; 1244: 142–154. 251. Balaratnasingam C, Morgan WH, Bass L, Cringle SJ, Yu DY. Time-dependent effects of elevated intraocular pressure on optic nerve head axonal transport and cytoskeleton proteins. Invest Ophthalmol Vis Sci 2008; 49: 986–999. 252. Morgan JE. Optic nerve head structure in glaucoma: astrocytes as mediators of axonal damage. Eye (Lond) 2000; 14: 437–444. 253. Leist M, Nicotera P. Calcium and neuronal death. Rev Physiol Biochem Pharmacol 1998; 132: 79–125. 254. Hartwick AT, Lalonde MR, Barnes S, Baldridge WH. Adenosine A1-receptor modulation of glutamate-induced calcium influx in rat retinal ganglion cells. Invest Ophthalmol Vis Sci 2004; 45: 3740–3748. 255. Ward MM, Jobling AI, Kalloniatis M, Fletcher EL. Glutamate uptake in retinal glial cells during diabetes. Diabetologia 2005; 48: 351–360. 256. Kowluru RA, Engerman RL, Case GL, Kern TS. Retinal glutamate in diabetes and effect of antioxidants. Neurochem Int 2001; 38: 385–390. 257. Li Q, Puro DG. Diabetes-induced dysfunction of the glutamate transporter in retinal Müller cells. Invest Ophthalmol Vis Sci 2002; 43: 3109–3116. 258. Roberts MD, Grau V, Grimm J, Reynaud J, Bellezza AJ, Burgoyne CF, Downs JC. Remodeling of the connective tissue microarchitecture of the lamina cribrosa in early experimental glaucoma. Invest Ophthalmol Vis Sci 2009; 50: 681– 690. 259. Yang H, Downs JC, Burgoyne CF. Physiologic inter-eye differences in monkey optic nerve head architecture and their relation to changes in early experimental glaucoma. Invest Ophthalmol Vis Sci 2009; 50: 224–234. 260. Johnson EC, Morrison JC, Farrell S, Deppmeier L, Moore CG, McGinty MR. The effect of chronically elevated intraocular pressure on the rat optic nerve head extracellular matrix. Exp Eye Res 1996; 62: 663–674. 261. Morgan JE, Jeffery G, Foss AJ. Axon deviation in the human lamina cribrosa. Br J Ophthalmol 1998; 82: 680–683.



262. Quigley HA, Guy J, Anderson DR. Blockade of rapid axonal transport. Effect of intraocular pressure elevation in primate optic nerve. Arch Ophthalmol 1979; 97: 525–531. 263. Francis-Sedlak ME, Uriel S, Larson JC, Greisler HP, Venerus DC, Brey EM. Characterization of type I collagen gels modified by glycation. Biomaterials 2009; 30: 1851–1856. 264. Leibowitz HM, Krueger DE, Maunder LR, Milton RC, Kini MM, Kahn HA, Nickerson RJ et al. The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973–1975. Surv Ophthalmol 1980; 24: 335–610. 265. Le A, Mukesh BN, McCarty CA, Taylor HR. Risk factors associated with the incidence of open-angle glaucoma: the visual impairment project. Invest Ophthalmol Vis Sci 2003; 44: 3783– 3789. 266. Hennis A, Wu SY, Nemesure B, Leske MC. Hypertension, diabetes and longitudinal changes in intraocular pressure. Ophthalmology 2003; 110: 908–914. 267. Pasquale LR, Kang JH, Manson JE, Willett WC, Rosner BA, Hankinson SE. Prospective study of type 2 diabetes mellitus and risk of primary openangle glaucoma in women. Ophthalmology 2006; 113: 1081–1086. 268. Miglior S, Pfeiffer N, Torri V, Zeyen T, CunhaVaz J, Adamsons I. Predictive factors for openangle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study. Ophthalmology 2007; 114: 3–9. 269. Chopra V, Varma R, Francis BA, Wu J, Torres M, Azen SP. Type 2 diabetes mellitus and the risk of open-angle glaucoma the Los Angeles Latino Eye Study. Ophthalmology 2008; 115: 227–232. 270. Ciulla TA, Harris A, Latkany P, Piper HC, Arend O, Garzozi H, Martin B. Ocular perfusion abnormalities in diabetes. Acta Ophthalmol Scand 2002; 80: 468–477. 271. Pemp B, Georgopoulos M, Vass C, FuchsjagerMayrl G, Luksch A, Rainer G, Schmetterer L. Diurnal fluctuation of ocular blood flow parameters in patients with primary open-angle glaucoma and healthy subjects. Br J Ophthalmol 2009; 93: 486–491. 272. Su EN, Yu DY, Alder VA, Yu PK, Cringle SJ. Altered vasoactivity in the early diabetic eye: measured in the isolated perfused rat eye. Exp Eye Res 1995; 61: 699–711. 273. Nathanson JA, McKee M. Alterations of ocular nitric oxide synthase in human glaucoma. Invest Ophthalmol Vis Sci 1995; 36: 1774–1784. 274. Garcia-Valenzuela E, Shareef S, Walsh J, Sharma SC. Programmed cell death of retinal ganglion cells during experimental glaucoma. Exp Eye Res 1995; 61: 33–44. 275. Quigley HA. Ganglion cell death in glaucoma: pathology recapitulates ontogeny. Aust NZ J Ophthalmol 1995; 23: 85–91. 276. Gao H, Qiao X, Cantor LB, WuDunn D. Up-regulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells. Arch Ophthalmol 2002; 120: 797– 803. 277. Chintala SK, Zhang X, Austin JS, Fini ME. Deficiency in matrix metalloproteinase gelatinase B (MMP-9) protects against retinal ganglion cell

death after optic nerve ligation. J Biol Chem 2002; 277: 47461–47468.

Corresponding author: Dr Bang V Bui Department of Optometry and Vision Sciences The University of Melbourne Parkville VIC 3010 AUSTRALIA E-mail: [email protected]



23